Lars Farde

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2024;27(5):pyae021
Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect
Garde M; Matheson GJ; Varnaes K; Svenningsson P; Hedman-Lagerloef E; Lundberg J; Farde L; Tiger M
Article: JOURNAL OF ALZHEIMERS DISEASE. 2024;98(4):1391-1401
High Contrast PET Imaging of Subcortical and Allocortical Amyloid-β in Early Alzheimer's Disease Using [¹¹C]AZD2184
Mattsson P; Cselenyi Z; Moren AF; Freund-Levi Y; Wahlund L-O; Halldin C; Farde L
Article: ACS CHEMICAL NEUROSCIENCE. 2023;14(17):3206-3211
PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [¹⁸F]GEH200449 for Detection of Monoamine Oxidase-B in the Non-Human Primate Brain
Varnas K; Nag S; Halldin C; Farde L
Article: SYNAPSE. 2023;77(4):e22269
[¹¹C]PBB3 binding in Aβ(-) or Aβ(+) corticobasal syndrome
Cselenyi Z; Wallin J; Tjerkoski J; Bloth B; Svensson S; Nennesmo I; Sunnemark D; Jelic V; Farde L; Svenningsson P
Article: SCHIZOPHRENIA RESEARCH. 2023;257:34-40
CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance
Orhan F; Goiny M; Becklen M; Mathe L; Piehl F; Schwieler L; Fatouros-Bergman H; Farde L; Cervenka S; Sellgren CM; Engberg G; Erhardt S
Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2023;16(6):955-965
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
Ekman S; Cselenyi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnstrom P; Laus G; Lewensohn R; Brown AP; van der Aart J; Vishwanathan K; Farde L
Article: ADDICTION. 2023;118(6):1053-1061
Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers
Jangard S; Jayaram-Lindstrom N; Isacsson NH; Matheson GJ; Plaven-Sigray P; Franck J; Borg J; Farde L; Cervenka S
Article: ACS CHEMICAL NEUROSCIENCE. 2022;13(14):2078-2083
Synthesis and Preclinical Evaluation of [¹¹C]AZ11895530 for PET Imaging of the Serotonin 1A Receptor
Dahl K; Johnstrom P; Forsberg-Moren A; Gustafsson B; Miranda-Azpiazu P; Khani Y; Halldin C; Farde L; Elmore CS; Schou M
Article: SYNAPSE. 2022;76(7-8):e22235
Decreased 5-HT_1A binding in mild Alzheimer's disease-A positron emission tomography study
Mattsson P; Cselenyi Z; Andree B; Borg J; Nag S; Halldin C; Farde L
Article: MOLECULAR PSYCHIATRY. 2022;27(2):1233-1240
Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis
Plaven-Sigray P; Ikonen Victorsson P; Santillo A; Matheson GJ; Lee M; Collste K; Fatouros-Bergman H; Sellgren CM; Erhardt S; Agartz I; Halldin C; Farde L; Cervenka S
Article: MOVEMENT DISORDERS. 2022;37(1):119-129
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹C]PBR28 and Machine Learning Analysis
Jucaite A; Cselenyi Z; Kreisl WC; Rabiner EA; Varrone A; Carson RE; Rinne JO; Savage A; Schou M; Johnstrom P; Svenningsson P; Rascol O; Meissner WG; Barone P; Seppi K; Kaufmann H; Wenning GK; Poewe W; Farde L
Article: NPJ SCHIZOPHRENIA. 2021;7(1):46
No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis
Lee M; Fatouros-Bergman H; Plaven-Sigray P; Victorsson PI; Sellgren CM; Erhardt S; Flyckt L; Farde L; Cervenka S
Article: MOLECULAR PSYCHIATRY. 2021;26(5):1647-1658
Serotonin transporter availability in adults with autism-a positron emission tomography study
Andersson M; Tangen A; Farde L; Bolte S; Halldin C; Borg J; Lundberg J
Article: NEURO-ONCOLOGY. 2021;23(4):687-696
Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study
Jucaite A; Stenkrona P; Cselenyi Z; De Vita S; Buil-Bruna N; Varnas K; Savage A; Varrone A; Johnstrom P; Schou M; Davison C; Sykes A; Reddy VP; Hoch M; Vazquez-Romero A; Moein MM; Halldin C; Merchant MS; Pass M; Farde L
Article: NEUROIMAGE. 2021;226:117523
Low convergent validity of [¹¹C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [¹¹C]FLB 457
Freiburghaus T; Svensson JE; Matheson GJ; Plaven-Sigray P; Lundberg J; Farde L; Cervenka S
Article: CLINICAL CANCER RESEARCH. 2021;27(1):189-201
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs
Colclough N; Chen K; Johnstrom P; Strittmatter N; Yan Y; Wrigley GL; Schou M; Goodwin R; Varnas K; Adua SJ; Zhao M; Nguyen DX; Maglennon G; Barton P; Atkinson J; Zhang L; Janefeldt A; Wilson J; Smith A; Takano A; Arakawa R; Kondrashov M; Malmquist J; Revunov E; Vazquez-Romero A; Moein MM; Windhorst AD; Karp NA; Finlay MRV; Ward RA; Yates JWT; Smith PD; Farde L; Cheng Z; Cross DAE
Article: BRITISH JOURNAL OF ANAESTHESIA. 2021;126(1):238-244
Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo
Varnas K; Finnema SJ; Johnstrom P; Arakawa R; Halldin C; Eriksson LI; Farde L
Article: ACS CHEMICAL NEUROSCIENCE. 2020;11(24):4398-4404
Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B
Nag S; Jia Z; Svedberg M; Jackson A; Ahmad R; Luthra S; Varnas K; Farde L; Halldin C
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2020;47(10):2407-2416
High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort
Fazio P; Ferreira D; Svenningsson P; Halldin C; Farde L; Westman E; Varrone A
Article: NATURE COMMUNICATIONS. 2020;11(1):4016
The genetic architecture of human brainstem structures and their involvement in common brain disorders
Elvsashagen T; Bahrami S; van der Meer D; Agartz I; Alnaes D; Barch DM; Baur-Streubel R; Bertolino A; Beyer MK; Blasi G; Borgwardt S; Boye B; Buitelaar J; Boen E; Celius EG; Cervenka S; Conzelmann A; Coynel D; Di Carlo P; Djurovic S; Eisenacher S; Espeseth T; Fatouros-Bergman H; Flyckt L; Franke B; Frei O; Gelao B; Harbo HF; Hartman CA; Haberg A; Heslenfeld D; Hoekstra PJ; Hogestol EA; Jonassen R; Jonsson EG; Kirsch P; Kloszewska I; Lagerberg TV; Landro NI; Le Hellard S; Lesch K-P; Maglanoc LA; Malt UF; Mecocci P; Melle I; Meyer-Lindenberg A; Moberget T; Nordvik JE; Nyberg L; O'Connell KS; Oosterlaan J; Papalino M; Papassotiropoulos A; Pauli P; Pergola G; Persson K; de Quervain D; Reif A; Rokicki J; van Rooij D; Shadrin AA; Schmidt A; Schwarz E; Selbaek G; Soininen H; Sowa P; Steen VM; Tsolaki M; Vellas B; Wang L; Westman E; Ziegler GC; Zink M; Andreassen OA; Westlye LT; Kaufmann T; Farde L; Flyckt L; Engberg G; Erhardt SS; Fatouros-Bergman H; Cervenka S; Schwieler L; Piehl F; Agartz I; Collste K; Victorsson P; Malmqvist A; Hedberg M; Orhan F; Sellgren CM
Article: SCHIZOPHRENIA RESEARCH. 2020;222:175-184
Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness
Matheson GJ; Plaven-Sigray P; Louzolo A; Borg J; Farde L; Petrovic P; Cervenka S
Article: EJNMMI RESEARCH. 2020;10(1):77
Kinfitr - an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability
Tjerkaski J; Cervenka S; Farde L; Matheson GJ
Article: EJNMMI RESEARCH. 2020;10(1):59
Quantification and reliability of [¹¹C]VC-002 binding to muscarinic acetylcholine receptors in the human lung - a test-retest PET study in control subjects
Cselenyi Z; Jucaite A; Kristensson C; Stenkrona P; Ewing P; Varrone A; Johnstrom P; Schou M; Vazquez-Romero A; Moein MM; Bolin M; Siikanen J; Gryback P; Larsson B; Halldin C; Grime K; Eriksson UG; Farde L
Article: ACS CHEMICAL NEUROSCIENCE. 2020;11(7):1048-1057
Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: ¹⁸F-AZD9272
Nag S; Varnas K; Arakawa R; Jahan M; Schou M; Farde L; Halldin C
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2020;40(4):799-807
A PET study in healthy subjects of brain exposure of ¹¹C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer
Varrone A; Varnas K; Jucaite A; Cselenyi Z; Johnstrom P; Schou M; Vazquez-Romero A; Moein MM; Halldin C; Brown AP; Vishwanathan K; Farde L
Article: PSYCHIATRY AND CLINICAL NEUROSCIENCES. 2020;74(4):263-269
[¹¹C]raclopride positron emission tomography study of dopamine-D_2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects
Tiger M; Svensson J; Liberg B; Saijo T; Schain M; Halldin C; Farde L; Lundberg J
Article: NEUROPHARMACOLOGY. 2020;162:107809
The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans
Varnas K; Cselenyi Z; Arakawa R; Nag S; Stepanov V; Moein MM; Johnstrom P; Kingston L; Elmore CS; Halldin C; Farde L
Article: EJNMMI RESEARCH. 2019;9(1):100
Potential for imaging the high-affinity state of the 5-HT_1B receptor: a comparison of three PET radioligands with differing intrinsic activity
Lindberg A; Arakawa R; Nogami T; Nag S; Schou M; Elmore CS; Farde L; Pike VW; Halldin C
Article: NEUROIMAGE. 2019;202:116143
Validity and reliability of extrastriatal [¹¹C]raclopride binding quantification in the living human brain
Svensson JE; Schain M; Plaven-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2019;46(11):2329-2338
Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [¹¹C]PBR28 HRRT PET study
Tuisku J; Plaven-Sigray P; Gaiser EC; Airas L; Al-Abdulrasul H; Bruck A; Carson RE; Chen M-K; Cosgrove KP; Ekblad L; Esterlis I; Farde L; Forsberg A; Halldin C; Helin S; Kosek E; Lekander M; Lindgren N; Marjamaki P; Rissanen E; Sucksdorff M; Varrone A; Collste K; Gallezot J-D; Hillmer A; Huang Y; Hoglund CO; Johansson J; Jucaite A; Lampa J; Nabulsi N; Pittman B; Sandiego CM; Stenkrona P; Rinne J; Matuskey D; Cervenka S
Article: NATURE NEUROSCIENCE. 2019;22(10):1617-1623
Common brain disorders are associated with heritable patterns of apparent aging of the brain
Kaufmann T; van der Meer D; Nhat TD; Schwarz E; Lund MJ; Agartz I; Alnaes D; Barch DM; Baur-Streubel R; Bertolino A; Bettella F; Beyer MK; Boen E; Borgwardt S; Brandt CL; Buitelaar J; Celius EG; Cervenka S; Conzelmann A; Cordova-Palomera A; Dale AM; de Quervain DJF; Carlo P; Djurovic S; Dorum ES; Eisenacher S; Elvsashagen T; Espeseth T; Fatouros-Bergman H; Flyckt L; Franke B; Frei O; Haatveit B; Haberg AK; Harbo HF; Hartman CA; Heslenfeld D; Hoekstra PJ; Hogestol EA; Jernigan TL; Jonassen R; Jonsson EG; Kirsch P; Ktoszewska I; Kolskar KK; Landro NI; Hellard S; Lesch K-P; Lovestone S; Lundervold A; Lundervold AJ; Maglanoc LA; Malt UF; Mecocci P; Melle I; Meyer-Lindenberg A; Moberget T; Norbom LB; Nordvik JE; Nyberg L; Oosterlaan J; Papalino M; Papassotiropoulos A; Pauli P; Pergola G; Persson K; Richard G; Rokicki J; Sanders A-M; Selbaek G; Shadrin AA; Smeland OB; Soininen H; Sowa P; Steen VM; Tsolaki M; Ulrichsen KM; Vellas B; Wang L; Westman E; Ziegler GC; Zink M; Andreassen OA; Westlye LT; Farde L; Flyckts L; Engberg G; Erhardt S; Fatouros-Bergmann H; Schwieler L; Piehl F; Collste K; Victorsson P; Malmqvist A; Hedberg M; Orhan F
Article: JOURNAL OF NEUROIMMUNOLOGY. 2019;334:577000
Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [¹¹C]PBR28 positron emission tomography
Forsberg A; Lampa J; Estelius J; Cervenka S; Farde L; Halldin C; Lekander M; Hoglund OC; Kosek E
Article: NEUROPSYCHOPHARMACOLOGY. 2019;44(10):1706-1713
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain
Yang K-C; Stepanov V; Amini N; Martinsson S; Takano A; Bundgaard C; Bang-Andersen B; Sanchez C; Halldin C; Farde L; Finnema SJ
Article: SCHIZOPHRENIA RESEARCH. 2019;210:221-227
Increased peripheral levels of TARC/CCL17 in first episode psychosis patients
Malmqvist A; Schwieler L; Orhan F; Fatouros-Bergman H; Bauer M; Flyckt L; Cervenka S; Engberg G; Piehl F; Erhardt S; Farde L; Flyckt L; Engberg G; Erhardt S; Fatouros-Bergman H; Cervenka S; Schwieler L; Piehl F; Agartz I; Collste K; Victorsson P; Malmqvist A; Hedberg M; Orhan F
Article: JAMA PSYCHIATRY. 2019;76(7):739-748
Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk
Alnaes D; Kaufmann T; van der Meer D; Cordova-Palomera A; Rokicki J; Moberget T; Bettella F; Agartz I; Barch DM; Bertolino A; Brandt CL; Cervenka S; Djurovic S; Nhat TD; Eisenacher S; Fatouros-Bergman H; Flyckt L; Di Giorgio A; Haatveit B; Jonsson EG; Kirsch P; Lund MJ; Meyer-Lindenberg A; Pergola G; Schwarz E; Smeland OB; Quarto T; Zink M; Andreassen OA; Westlye LT; Farde L; Collste K; Victorsson P; Engberg G; Erhardt S; Malmqvist A; Hedberg M; Orhan F; Sellgren CM; Schwieler L; Piehl F
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2019;22(7):415-425
D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients
Stenkrona P; Matheson GJ; Halldin C; Cervenka S; Farde L
Article: NEUROIMAGE. 2019;188:102-110
Accuracy and reliability of [¹¹C]PBR28 specific binding estimated without the use of a reference region
Plaven-Sigray P; Schain M; Zanderigo F; Farde L; Halldin C; Forsberg A; Varrone A; Jucaite A; Cervenka S; Stenkrona P; Collste K; Kander M; Kosek E; Lampa J; Hoglund CO; Rabiner EA; Gunn RN; Ogden RT; Cervenk S
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2019;46(2):367-375
PET imaging of [¹¹C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding
Varnas K; Cselenyi Z; Jucaite A; Halldin C; Svenningsson P; Farde L; Varrone A
Article: EJNMMI RESEARCH. 2019;9(1):9
Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator
Schou M; Ewing P; Cselenyi Z; Friden M; Takano A; Halldin C; Farde L
Article: TRANSLATIONAL PSYCHIATRY. 2019;9(1):12
Reproducible grey matter patterns index a multivariate, global alteration of brain structure in schizophrenia and bipolar disorder
Schwarz E; Nhat TD; Pergola G; Westlye LT; Kaufmann T; Wolfers T; Brecheisen R; Quarto T; Ing AJ; Di Carlo P; Gurholt TP; Harms RL; Noirhomme Q; Moberget T; Agartz I; Andreassen OA; Bellani M; Bertolino A; Blasi G; Brambilla P; Buitelaar JK; Cervenka S; Flyckt L; Frangou S; Franke B; Hall J; Heslenfeld DJ; Kirsch P; McIntosh AM; Noethen MM; Papassotiropoulos A; de Quervain DJ-F; Rietschel M; Schumann G; Tost H; Witt SH; Zink M; Meyer-Lindenberg A; Bettella F; Brandt CL; Clarke T-K; Coynel D; Degenhardt F; Djurovic S; Eisenacher S; Fastenrath M; Fatouros-Bergman H; Forstner AJ; Frank J; Gambi F; Gelao B; Geschwind L; Di Giannantonio M; Di Giorgio A; Hartman CA; Heilmann-Heimbach S; Herms S; Hoekstra PJ; Hoffmann P; Hoogman M; Jonsson EG; Loos E; Maggioni E; Oosterlaan J; Papalino M; Rampino A; Romaniuk L; Selvaggi P; Sepede G; Sonderby IE; Spalek K; Sussmann JE; Thompson PM; Vasquez AA; Vogler C; Whalley H; Farde L; Flyckt L; Engberg G; Erhardt S; Fatouros-Bergman H; Cervenka S; Schwieler L; Agartz I; Collste K; Victorsson P; Malmqvist A; Hedberg M; Orhan F
Article: EJNMMI RESEARCH. 2018;8(1):113
The development of a GPR44 targeting radioligand [¹¹C]AZ12204657 for in vivo assessment of beta cell mass
Jahan M; Johnstrom P; Selvaraju RK; Svedberg M; Winzell MS; Bernstrom J; Kingston L; Schou M; Jia Z; Skrtic S; Johansson L; Korsgren O; Farde L; Halldin C; Eriksson O
Article: EJNMMI RESEARCH. 2018;8(1):102
Test-retest reliability and convergent validity of (R)-[¹¹C]PK11195 outcome measures without arterial input function
Plaven-Sigray P; Matheson GJ; Cselenyi Z; Jucaite A; Farde L; Cervenka S
Article: ACTA PSYCHIATRICA SCANDINAVICA. 2018;138(5):432-440
Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis
Orhan F; Schwieler L; Fatouros-Bergman H; Malmqvist A; Cervenka S; Collste K; Flyckt L; Farde L; Sellgren CM; Piehl F; Engberg G; Erhardt S
Article: SCIENCE TRANSLATIONAL MEDICINE. 2018;10(461):eaam8434
GABA_A receptor availability is not altered in adults with autism spectrum disorder or in mouse models
Horder J; Andersson M; Mendez MA; Singh N; Tangen A; Lundberg J; Gee A; Halldin C; Veronese M; Bolte S; Farde L; Sementa T; Cash D; Higgins K; Spain D; Turkheimer F; Mick I; Selvaraj S; Nutt DJ; Lingford-Hughes A; Howes OD; Murphy DG; Borg J
Article: EJNMMI RESEARCH. 2018;8(1):74
[¹¹C]SCH23390 binding to the D₁-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis
Stenkrona P; Matheson GJ; Cervenka S; Sigray PP; Halldin C; Farde L
Article: TRANSLATIONAL PSYCHIATRY. 2018;8(1):132
Serotonin concentration enhancers at clinically relevant doses reduce [¹¹C] AZ10419369 binding to the 5-HT_1B receptors in the nonhuman primate brain
Yang K-C; Takano A; Halldin C; Farde L; Finnema SJ
Article: NEUROPHARMACOLOGY. 2018;135:455-463
The metabotropic glutamate receptor 5 radioligand [¹¹C]AZD9272 identifies unique binding sites in primate brain
Varnas K; Jureus A; Finnema SJ; Johnstrom P; Raboisson P; Amini N; Takano A; Stepanov V; Halldin C; Farde L
Article: MOLECULAR IMAGING AND BIOLOGY. 2018;20(2):183-187
Potential Effect of Prolonged Sevoflurane Anesthesia on the Kinetics of [¹¹C]Raclopride in Non-human Primates
Arakawa R; Farde L; Matsumoto J; Kanegawa N; Yakushev I; Yang K-C; Takano A
Article: MOVEMENT DISORDERS. 2018;33(4):592-599
Nigrostriatal dopamine transporter availability in early Parkinson's disease
Fazio P; Svenningsson P; Cselenyi Z; Halldin C; Farde L; Varrone A
Article: EUROPEAN PSYCHIATRY. 2018;50:21-27
The MINDVIEW project: First results
Benlloch JM; Gonzalez AJ; Pani R; Preziosi E; Jackson C; Murphy J; Barbera J; Correcher C; Aussenhofer S; Gareis D; Visvikis D; Bert J; Langstrom B; Farde L; Toth M; Haggkvist J; Caixeta FV; Kullander K; Somlai-Schweiger I; Schwaiger M
Article: PEERJ. 2018;6:e5790
Serotonin 5-HT₁_A receptor binding and self-transcendence in healthy control subjects-a replication study using Bayesian hypothesis testing
Griffioen G; Matheson GJ; Cervenka S; Farde L; Borg J
Article: PLOS ONE. 2018;13(3):e0193770
Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study
Plaven-Sigray P; Matheson GJ; Gustavsson P; Stenkrona P; Halldin C; Farde L; Cervenka S
Article: EJNMMI RESEARCH. 2017;7(1):58
Assessment of simplified ratio-based approaches for quantification of PET [¹¹C] PBR28 data
Matheson GJ; Plaven-Sigray P; Forsberg A; Varrone A; Farde L; Cervenka S
Article: JOURNAL OF ALZHEIMER'S DISEASE REPORTS. 2017;1(1):169-180
Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [¹⁸F]FDG-μPET Study
Venzi M; Toth M; Haggkvist J; Bogstedt A; Rachalski A; Mattsson A; Frumento P; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2017;54:34-40
[¹¹C]AZ10419096-a full antagonist PET radioligand for imaging brain 5-HT_1B receptors
Lindberg A; Nag S; Schou M; Takano A; Matsumoto J; Amini N; Elmore CS; Farde L; Pike VW; Haildin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2017;20(9):683-691
Fenfluramine Reduces [¹¹C] Cimbi-36 Binding to the 5-HT_2A Receptor in the Nonhuman Primate Brain
Yang K-C; Stepanov V; Martinsson S; Ettrup A; Takano A; Knudsen GM; Halldin C; Farde L; Finnema SJ
Article: NEUROIMAGE. 2017;155:344-353
Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [¹¹C] SCH-23390
Matheson GJ; Stenkrona P; Cselenyi Z; Plaven-Sigray P; Halldin C; Farde L; Cervenka S
Article: MOLECULAR PSYCHIATRY. 2017;22(6):850-856
Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [¹¹C]PBR28
Collste K; Plaven-Sigray P; Fatouros-Bergman H; Victorsson P; Schain M; Forsberg A; Amini N; Aeinehband S; Erhardt S; Halldin C; Flyckt L; Farde L; Cervenka S
Article: ANNALS OF NEUROLOGY. 2017;81(4):572-582
The Immune Response of the Human Brain to Abdominal Surgery
Forsberg A; Cervenka S; Fagerlund MJ; Rasmussen LS; Zetterberg H; Harris HE; Stridh P; Christensson E; Granstrom A; Schening A; Dymmel K; Knave N; Terrando N; Maze M; Borg J; Varrone A; Halldin C; Blennow K; Farde L; Eriksson LI
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2017;44(2):308-320
Characterization of [¹¹C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain
Yang K-C; Stepanov V; Amini N; Martinsson S; Takano A; Nielsen J; Bundgaard C; Bang-Andersen B; Grimwood S; Halldin C; Farde L; Finnema SJ
Article: PSYCHOPHARMACOLOGY. 2017;234(4):707-716
GABA_A receptor occupancy by subtype selective GABA_Aα2,3 modulators: PET studies in humans
Jucaite A; Cselenyi Z; Lappalainen J; McCarthy DJ; Lee C-M; Nyberg S; Varnas K; Stenkrona P; Halldin C; Cross A; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 2016;57(10):1529-1534
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using ¹⁸F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
Sonni I; Fazio P; Sehain M; Halldin C; Svenningsson P; Farde L; Varrone A
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2016;358(3):464-471
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676
Varnas K; Jureus A; Johnstrom P; Ahlgren C; Schott P; Schou M; Gruber S; Jerning E; Malmborg J; Halldin C; Afzelius L; Farde L
Article: MOLECULAR PSYCHIATRY. 2016;21(8):1077-1084
Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain
Borg J; Cervenka S; Kuja-Halkola R; Matheson GJ; Jonsson EG; Lichtenstein P; Henningsson S; Ichimiya T; Larsson H; Stenkrona P; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2016;19(8):pyw023
Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [¹⁸F]Lu AF10628
Varnas K; Finnema SJ; Stepanov V; Takano A; Toth M; Svedberg M; Nielsen SM; Khanzhin NA; Juhl K; Bang-Andersen B; Halldin C; Farde L
Article: PSYCHIATRY RESEARCH-NEUROIMAGING. 2016;253:36-42
Low serotonin_1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder
Tiger M; Farde L; Ruck C; Varrone A; Forsberg A; Lindefors N; Halldin C; Lundberg J
Article: NEUROIMAGE. 2016;133:313-320
Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data
Fazio P; Schain M; Varnas K; Halldin C; Farde L; Varrone A
Article: BRAIN BEHAVIOR AND IMMUNITY. 2016;54:149-157
In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects
Kanegawa N; Collste K; Forsberg A; Schain M; Arakawa R; Jucaite A; Lekander M; Hoglund CO; Kosek E; Lampa J; Halldin C; Farde L; Varrone A; Cervenka S
Article: ACS CHEMICAL NEUROSCIENCE. 2016;7(2):177-184
Discovery and Preclinical Validation of [¹¹C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor
Schou M; Varnas K; Jureus A; Ahlgren C; Malmquist J; Haggkvist J; Tari L; Wesolowski SS; Throner SR; Brown DG; Nilsson M; Johnstrom P; Finnema SJ; Nakao R; Amini N; Takano A; Farde L
Article: NEUROPHARMACOLOGY. 2016;101:519-530
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates
Hjorth S; Karlsson C; Jucaite A; Varnas K; Hamren UW; Johnstrom P; Gulyas B; Donohue SR; Pike VW; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2016;43(1):173-183
Test-retest reproducibility of [¹¹C]PBR28 binding to TSPO in healthy control subjects
Collste K; Forsberg A; Varrone A; Amini N; Aeinehband S; Yakushev I; Halldin C; Farde L; Cervenka S
Article: JOURNAL OF NEUROCHEMISTRY. 2015;135(5):859-866
Distinct binding of amyloid imaging ligands to unique amyloid-b deposited in the presubiculum of Alzheimer's disease
Ji B; Chen C-J; Bando K; Ashino H; Shiraishi H; Sano H; Kasahara H; Minamizawa T; Yamada K; Ono M; Zhang M-R; Seki C; Farde L; Suhara T; Higuchi M
Article: PSYCHOPHARMACOLOGY. 2015;232(21-22):4159-4167
Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [¹¹C]MADAM PET study
Finnema SJ; Halldin C; Bang-Andersen B; Bundgaard C; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2015;42(11):893-898
Synthesis of ([¹¹C]carbonyl)raclopride and a comparison with ([¹¹C]methyl)raclopride in a monkey PET study
Rahman O; Takano A; Amini N; Dahl K; Kanegawa N; Langstrom B; Farde L; Halldin C
Article: BRAIN. 2015;138(Pt 9):2687-2700
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease
Jucaite A; Svenningsson P; Rinne JO; Cselenyi Z; Varnas K; Johnstrom P; Amini N; Kirjavainen A; Helin S; Minkwitz M; Kugler AR; Posener JA; Budd S; Halldin C; Varrone A; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2015;42(10):1507-1511
β-Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [¹¹C]AZD2184
Mattsson P; Forsberg A; Persson J; Nyberg L; Nilsson L-G; Halldin C; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2015;35(9):1485-1493
Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio
Cselenyi Z; Farde L
Article: SYNAPSE. 2015;69(7):365-374
5-HT_1B receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients
Varrone A; Svenningsson P; Marklund P; Fatouros-Bergman H; Forsberg A; Halldin C; Nilsson L-G; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2015;42(6):555-560
Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing
Johnstrom P; Bergman L; Varnas K; Malmquist J; Halldin C; Farde L
Article: NEUROIMAGE. 2015;112:225-231
Diurnal and seasonal variation of the brain serotonin system in healthy male subjects
Matheson GJ; Schain M; Almeida R; Lundberg J; Cselenyi Z; Borg J; Varrone A; Farde L; Cervenka S
Article: JOURNAL OF NUCLEAR MEDICINE. 2015;56(5):714-720
Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
Fazio P; Svenningsson P; Forsberg A; Jonsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2015;18(10):pyv036
Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates
Schou M; Varnas K; Lundquist S; Nakao R; Amini N; Takano A; Finnema SJ; Halldin C; Farde L
Article: RSC ADVANCES. 2015;5(108):88886-88889
¹¹C-carbonylation reactions using gas-liquid segmented microfluidics
Dahl K; Schou M; Ulin J; Sjoberg C-O; Farde L; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2014;18(3):pyu081
Amphetamine Decreases α_2C-Adrenoceptor Binding of [¹¹C]ORM-13070: A PET Study in the Primate Brain
Finnema SJ; Hughes ZA; Haaparanta-Solin M; Stepanov V; Nakao R; Vamas K; Varrone A; Arponen E; Marjamaki P; Pohjanoksa K; Vuorilehto L; Babalola PA; Solin O; Grimwood S; Sallinen J; Farde L; Scheinin M; Halldin C
Article: EJNMMI RESEARCH. 2014;4(1):50-8
Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain
Friden M; Wennerberg M; Antonsson M; Sandberg-Stall M; Farde L; Schou M
Article: NEUROIMAGE. 2014;103:303-308
Distinct regional age effects on [¹¹C]AZ10419369 binding to 5-HT_1B receptors in the human brain
Nord M; Cselenyi Z; Forsberg A; Rosenqvist G; Tiger M; Lundberg J; Varrone A; Farde L
Article: NEUROIMAGE. 2014;102:590-595
Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study
Plaven-Sigray P; Gustavsson P; Farde L; Borg J; Stenkrona P; Nyberg L; Backman L; Cervenka S
Article: NEUROINFORMATICS. 2014;12(4):551-562
Evaluation of Two Automated Methods for PET Region of Interest Analysis
Schain M; Varnas K; Cselenyi Z; Halldin C; Farde L; Varrone A
Article: SCHIZOPHRENIA RESEARCH. 2014;158(1-3):156-162
Meta-analysis of cognitive performance in drug-naive patients with schizophrenia
Fatouros-Bergman H; Cervenka S; Flyckt L; Edman G; Farde L
Article: PSYCHIATRY RESEARCH. 2014;223(2):164-170
Reduced 5-HT_1B receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder
Tiger M; Ruck C; Forsberg A; Varrone A; Lindefors N; Halldin C; Farde L; Lundberg J
Article: JOURNAL OF NUCLEAR MEDICINE. 2014;55(7):1164-1170
¹⁸F-MCL-524, an ¹⁸F-Labeled Dopamine D₂ and D₃ Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study
Finnema SJ; Stepanov V; Nakao R; Sromek AW; Zhang T; Neumeyer JL; George SR; Seeman P; Stabin MG; Jonsson C; Farde L; Halldin C
Article: JOURNAL OF NUCLEAR MEDICINE. 2014;55(6):932-938
Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer ¹¹C-AZD2184
Ito H; Shimada H; Shinotoh H; Takano H; Sasaki T; Nogami T; Suzuki M; Nagashima T; Takahata K; Seki C; Kodaka F; Eguchi Y; Fujiwara H; Kimura Y; Hirano S; Ikoma Y; Higuchi M; Kawamura K; Fukumura T; Boo EL; Farde L; Suhara T
Article: NEUROBIOLOGY OF AGING. 2014;35(4):867-875
Positron emission tomography imaging of 5-hydroxytryptamine_1B receptors in Parkinson's disease
Varrone A; Svenningsson P; Forsberg A; Varnas K; Tiger M; Nakao R; Halldin C; Nilsson L-G; Farde L
Article: MOLECULAR IMAGING AND BIOLOGY. 2014;16(2):173-179
Synthesis, Radiolabeling, and In Vivo Pharmacokinetic Evaluation of the Amyloid Beta Radioligand [¹¹C]AZD4694 in Nonhuman Primates
Schou M; Varnas K; Sandell J; Johnstrom P; Cselenyi Z; Svensson S; Nakao R; Amini N; Bergman L; Sumic A; Gulyas B; Lindstrom-Boo E; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;41(2):301-307
Test-retest reliability of [¹¹C]AZ10419369 binding to 5-HT_1B receptors in human brain
Nord M; Finnema SJ; Schain M; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2013;16(10):2235-2244
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR
Nyberg S; Jucaite A; Takano A; Kagedal M; Cselenyi Z; Halldin C; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 2013;54(10):1825-1832
Performance Evaluation of the Small-Animal nanoScan PET/MRI System
Nagy K; Toth M; Major P; Patay G; Egri G; Haggkvist J; Varrone A; Farde L; Halldin C; Gulyas B
Article: SYNAPSE. 2013;67(9):586-595
The dopamine D₁ receptor agonist (S)-[¹¹C]N-methyl-NNC 01-0259 is not sensitive to changes in dopamine concentrationa positron emission tomography examination in the monkey brain
Finnema SJ; Bang-Andersen B; Jorgensen M; Christoffersen CT; Gulyas B; Wikstrom HV; Farde L; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2013;16(7):1577-1586
Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain
Nord M; Finnema SJ; Halldin C; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2013;40(6):747-754
Radiosynthesis and evaluation of new α₁-adrenoceptor antagonists as PET radioligands for brain imaging
Airaksinen AJ; Finnema SJ; Balle T; Varnas K; Bang-Andersen B; Gulyas B; Farde L; Halldin C
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2013;33(7):1058-1065
Arterial input function derived from pairwise correlations between PET-image voxels
Schain M; Benjaminsson S; Varnas K; Forsberg A; Halldin C; Lansner A; Farde L; Varrone A
Article: CEPHALALGIA. 2013;33(10):853-860
A PET study with [¹¹C]AZ10419369 to determine brain 5-HT_1B receptor occupancy of zolmitriptan in healthy male volunteers
Varnas K; Jucaite A; McCarthy DJ; Stenkrona P; Nord M; Halldin C; Farde L; Kanes S
Article: NUCLEAR MEDICINE AND BIOLOGY. 2013;40(4):547-553
Palladium mediated ¹¹C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [¹¹C]AZD9272
Andersson JD; Seneca N; Truong P; Wensbo D; Raboisson P; Farde L; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2013;16(4):763-769
Effects of amphetamine on the human brain opioid system - a positron emission tomography study
Guterstam J; Jayaram-Lindstrom N; Cervenka S; Frost JJ; Farde L; Halldin C; Franck J
Article: NUCLEAR MEDICINE AND BIOLOGY. 2013;40(3):410-414
Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate
Schou M; Varnas K; Jucaite A; Gulyas B; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;40(4):574-579
Test-retest reproducibility of dopamine D_2/3 receptor binding in human brain measured by PET with [¹¹C]MNPA and [¹¹C]raclopride
Kodaka F; Ito H; Kimura Y; Fujie S; Takano H; Fujiwara H; Sasaki T; Nakayama K; Halldin C; Farde L; Suhara T
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;40(4):580-593
Low background and high contrast PET imaging of amyloid-β with [¹¹C]AZD2995 and [¹¹C]AZD2184 in Alzheimer's disease patients
Forsberg A; Jureus A; Cselenyi Z; Eriksdotter M; Freund-Levi Y; Jeppsson F; Swahn B-M; Sandell J; Julin P; Schou M; Andersson J; Johnstrom P; Varnas K; Halldin C; Farde L; Svensson S
Article: PSYCHOPHARMACOLOGY. 2013;226(1):147-153
SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study
Takano A; Halldin C; Farde L
Article: NEUROIMAGE. 2013;67:1-6
Individual differences in the proneness to have flow experiences are linked to dopamine D2-receptor availability in the dorsal striatum
de Manzano O; Cervenka S; Jucaite A; Hellenas O; Farde L; Ullen F
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;40(2):228-237
Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT
Schain M; Toth M; Cselenyi Z; Arakawa R; Halldin C; Farde L; Varrone A
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15(8):1167-1172
Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder
Lundberg J; Tiger M; Landen M; Halldin C; Farde L
Article: EJNMMI RESEARCH. 2012;2:15
Kinetic analysis and test-retest variability of the radioligand [¹¹C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects
Jucaite A; Cselenyi Z; Arvidsson A; Ahlberg G; Julin P; Varnas K; Stenkrona P; Andersson J; Halldin C; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2012;32(4):685-695
Confirmation of fenfluramine effect on 5-HT_1B receptor binding of [¹¹C]AZ10419369 using an equilibrium approach
Finnema SJ; Varrone A; Hwang T-J; Halldin C; Farde L
Article: JOURNAL OF CELLULAR PHYSIOLOGY. 2012;227(4):1663-1669
Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism
Sestini S; Halldin C; Mansi L; Castagnoli A; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 2012;53(3):415-424
Clinical Validation of ¹⁸F-AZD4694, an Amyloid-β-Specific PET Radioligand
Cselenyi Z; Jonhagen ME; Forsberg A; Halldin C; Julin P; Schou M; Johnstrom P; Varnas K; Svensson S; Farde L
Article: NEUROIMAGE. 2012;60(1):800-807
Quantification of serotonin transporter availability with [¹¹C]MADAM - A comparison between the ECAT HRRT and HR systems
Schain M; Toth M; Cselenyi Z; Stenkrona P; Halldin C; Farde L; Varrone A
Article: NEUROIMAGE. 2012;59(4):3582-3593
Quantitative PET analyses of regional [¹¹C]PE2I binding to the dopamine transporter - Application to juvenile myoclonic epilepsy
Odano I; Varrone A; Savic I; Ciumas C; Karlsson P; Jucaite A; Halldin C; Farde L
Article: JOURNAL OF NEUROIMAGING. 2012;22(1):28-32
A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel-Based Morphometry
Comley RA; Cervenka S; Palhagen SE; Panagiotidis G; Matthews JC; Lai RY; Halldin C; Farde L; Nichols TE; Whitcher BJ
Article: ANALYTICAL CHEMISTRY. 2011;83(24):9694-9701
Qualitative and Quantitative MALDI Imaging of the Positron Emission Tomography Ligands Raclopride (a D2 Dopamine Antagonist) and SCH 23390 (a D1 Dopamine Antagonist) in Rat Brain Tissue Sections Using a Solvent-Free Dry Matrix Application Method
Goodwin RJA; Mackay CL; Nilsson A; Harrison DJ; Farde L; Andren PE; Iverson SL
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2011;14(10):1357-1366
Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects
Nord M; Nyberg S; Brogren J; Jucaite A; Halldin C; Farde L
Article: HUMAN BRAIN MAPPING. 2011;32(10):1626-1636
Extrastriatal Dopamine D₂ Receptor Binding in Huntington's Disease
Esmaeilzadeh M; Farde L; Karlsson P; Varrone A; Halldin C; Waters S; Tedroff J
Article: NEUROBIOLOGY OF AGING. 2011;32(10):1849-1856
Dopamine D₁ receptors and age differences in brain activation during working memory
Backman L; Karlsson S; Fischer H; Karlsson P; Brehmer Y; Rieckmann A; MacDonald SWS; Farde L; Nyberg L
Article: CEREBRAL CORTEX. 2011;21(9):2023-2032
Dopamine D1 Receptor Associations within and between Dopaminergic Pathways in Younger and Elderly Adults: Links to Cognitive Performance
Rieckmann A; Karlsson S; Karlsson P; Brehmer Y; Fischer H; Farde L; Nyberg L; Backman L
Article: NEUROIMAGE. 2011;57(2):346-351
Relationship of dopamine D1 receptor binding in striatal and extrastriatal regions to cognitive functioning in healthy humans
Karlsson S; Rieckmann A; Karlsson P; Farde L; Nyberg L; Backman L
Article: PSYCHOPHARMACOLOGY. 2011;216(2):279-286
NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo
Takano A; Nag S; Gulyas B; Halldin C; Farde L
Article: PSYCHOPHARMACOLOGY. 2011;213(2-3):533-545
Dose-dependent binding of AZD3783 to brain 5-HT_1B receptors in non-human primates and human subjects: a positron emission tomography study with [¹¹C]AZ10419369
Varnas K; Nyberg S; Karlsson P; Pierson ME; Kagedal M; Cselenyi Z; McCarthy D; Xiao A; Zhang M; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2011;14(1):83-89
Effect of risperidone on high-affinity state of dopamine D₂ receptors: a PET study with agonist ligand [¹¹C](R)-2-CH₃O-N-n-propylnorapomorphine
Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
Article: NUCLEAR MEDICINE AND BIOLOGY. 2011;38(2):261-272
Development of a PET radioligand for the central 5-HT_1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds
Andersson JD; Pierson ME; Finnema SJ; Gulyas B; Heys R; Elmore CS; Farde L; Halldin C
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2011;31(1):113-123
Quantitative analysis of [¹¹C]AZ10419369 binding to 5-HT_1B receptors in human brain
Varnas K; Nyberg S; Halldin C; Varrone A; Takano A; Karlsson P; Andersson J; McCarthy D; Smith M; Pierson ME; Soderstrom J; Farde L
Article: SYNAPSE. 2010;64(10):733-741
Radiosynthesis of the Candidate β-Amyloid Radioligand [¹¹C]AZD2184: Positron Emission Tomography Examination and Metabolite Analysis in Cynomolgus Monkeys
Andersson JD; Varnas H; Cselenyi Z; Gulyas B; Wensbo D; Finnema SJ; Swahn B-M; Svensson S; Nyberg S; Farde L; Halldin C
Article: JOURNAL OF NEUROCHEMISTRY. 2010;114(3):784-794
Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand
Jureus A; Swahn B-M; Sandell J; Jeppsson F; Johnson AE; Johnstrom P; Neelissen JAM; Sunnemark D; Farde L; Svensson SPS
Article: SYNAPSE. 2010;64(7):573-577
Fenfluramine-Induced Serotonin Release Decreases [¹¹C]AZ10419369 Binding to 5-HT_1B-Receptors in the Primate Brain
Finnema SJ; Varrone A; Hwang TJ; Gulyas B; Pierson ME; Halldin C; Farde L
Article: SYNAPSE. 2010;64(6):478-485
PET Studies of D2-Receptor Binding in Striatal and Extrastriatal Brain Regions: Biochemical Support In Vivo for Separate Dopaminergic Systems in Humans
Cervenka S; Varrone A; Fransen E; Halldin C; Farde L
Article: PLOS ONE. 2010;5(5):e10670
Thinking Outside a Less Intact Box: Thalamic Dopamine D2 Receptor Densities Are Negatively Related to Psychometric Creativity in Healthy Individuals
de Manzano O; Cervenka S; Karabanov A; Farde L; Ullen F
Article: NEUROSCIENCE. 2010;167(1):104-110
AGE-RELATED REDUCTION IN DOPAMINE D1 RECEPTORS IN THE HUMAN BRAIN: FROM LATE CHILDHOOD TO ADULTHOOD, A POSITRON EMISSION TOMOGRAPHY STUDY
Jucaite A; Forssberg H; Karlsson P; Halldin C; Farde L
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2010;107(16):7574-7579
Dopamine D2 receptor density in the limbic striatum is related to implicit but not explicit movement sequence learning
Karabanov A; Cervenka S; de Manzano O; Forssberg H; Farde L; Ullen F
Article: BIOLOGICAL PSYCHIATRY. 2010;67(6):575-580
Simulating Neurocognitive Aging: Effects of a Dopaminergic Antagonist on Brain Activity During Working Memory
Fischer H; Nyberg L; Karlsson S; Karlsson P; Brehmer Y; Rieckmann A; MacDonald SWS; Farde L; Backman L
Article: NEUROIMAGE. 2010;50(1):323-328
Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability
Cervenka S; Gustavsson JP; Halldin C; Farde L
Article: NEUROIMAGE. 2009;48(2):398-404
Modulation of striatal dopamine D1 binding by cognitive processing
Karlsson S; Nyberg L; Karlsson P; Fischer H; Thilers P; MacDonald S; Brehmer Y; Rieckmann A; Halldin C; Farde L; Backman L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36(11):1859-1863
Detection of amyloid in Alzheimer's disease with positron emission tomography using [¹¹C]AZD2184
Nyberg S; Jonhagen ME; Cselenyi Z; Halldin C; Julin P; Olsson H; Freund-Levi Y; Andersson J; Varnas K; Svensson S; Farde L
Article: BIOLOGICAL PSYCHIATRY. 2009;66(5):477-485
Genetic Variation in Brain-Derived Neurotrophic Factor Is Associated with Serotonin Transporter but Not Serotonin-1A Receptor Availability in Men
Henningsson S; Borg J; Lundberg J; Bah J; Lindstrom M; Ryding E; Jovanovic H; Saijo T; Inoue M; Rosen I; Traskman-Bendz L; Farde L; Eriksson E
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2009;12(6):783-792
Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT_1A receptor binding in humans
Borg J; Henningsson S; Saijo T; Inoue M; Bah J; Westberg L; Lundberg J; Jovanovic H; Andree B; Nordstrom A-L; Halldin C; Eriksson E; Farde L
Article: NEUROSCIENCE. 2009;161(2):422-426
AGE-RELATED LOSS OF OLFACTORY SENSITIVITY: ASSOCIATION TO DOPAMINE TRANSPORTER BINDING IN PUTAMEN
Larsson M; Farde L; Hummel T; Witt M; Lindroth NE; Backman L
Article: JOURNAL OF NUCLEAR MEDICINE. 2009;50(5):703-710
Quantitative PET Analysis of the Dopamine D₂ Receptor Agonist Radioligand ¹¹C-(R)-2-CH₃O-N-n-Propylnorapomorphine in the Human Brain
Otsuka T; Ito H; Halldin C; Takahashi H; Takano H; Arakawa R; Okumura M; Kodaka F; Miyoshi M; Sekine M; Seki C; Nakao R; Suzuki K; Finnema S; Hirayasu Y; Suhara T; Farde L
Article: SYNAPSE. 2009;63(5):378-389
Dopamine D_2/3 Receptor Occupancy of Apomorphine in the Nonhuman Primate Brain-A Comparative PET Study With [¹¹C]Raclopride and [¹¹C]MNPA
Finnema SJ; Halldin C; Bang-Andersen B; Gulyas B; Bundgaard C; Wikstrom HV; Farde L
Article: NEUROIMAGE. 2009;45(3):891-902
[¹⁸F]Flumazenil binding to central benzodiazepine receptor studies by PET - Quantitative analysis and comparisons with [¹¹C]flumazenil
Odano I; Halldin C; Karlsson P; Varrone A; Airaksinen AJ; Krasikova RN; Farde L
Article: JOURNAL OF NEUROCHEMISTRY. 2009;108(5):1177-1186
AZD2184: a radioligand for sensitive detection of β-amyloid deposits
Johnson AE; Jeppsson F; Sandell J; Wensbo D; Neelissen JAM; Jureus A; Strom P; Norman H; Farde L; Svensson SPS
Article: SCIENCE. 2009;323(5915):800-802
Changes in Cortical Dopamine D1 Receptor Binding Associated with Cognitive Training
McNab F; Varrone A; Farde L; Jucaite A; Bystritsky P; Forssberg H; Klingberg T
Article: MOLECULAR IMAGING AND BIOLOGY. 2009;11(1):23-30
Investigation of the Metabolites of (S,S)-[¹¹C] MeNER in Humans, Monkeys and Rats
Schou M; Zoghbi SS; Shetty HU; Shchukin E; Liow J-S; Hong J; Andree BA; Gulyas B; Farde L; Innis RB; Pike VW; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2008;11(5):671-678
Age-related diurnal effect on D₂ receptor binding: a preliminary PET study
Cervenka S; Halldin C; Farde L
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2008;16(13):6467-6473
[¹¹C]cyclopropyl-FLB 457:: A PET radioligand for low densities of dopamine D₂ receptors
Airaksinen AJ; Nag S; Finnema SJ; Mukherjee J; Chattopadhyay S; Gulyas B; Farde L; Halldin C
Article: NEUROIMAGE. 2008;41(3):1075-1085
[¹¹C]AZ10419369:: A selective 5-HT_1B receptor radioligand suitable for positron emission tomography (PET).: Characterization in the primate brain
Pierson ME; Andersson J; Nyberg S; McCarthy DJ; Finnema SJ; Varnas K; Takano A; Karlsson P; Gulyas B; Medd AM; Lee C-M; Powell ME; Heys JR; Potts W; Seneca N; Mrzljak L; Farde L; Halldin C
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2008;28(5):1059-1069
Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [¹¹C]PE2I:: quantitative modeling and test-retest reproducibility
Hirvonen J; Johansson J; Teras M; Oikonen V; Lumme V; Virsu P; Roivainen A; Nagren K; Halldin C; Farde L; Hietala J
Article: NEUROIMAGE. 2008;40(3):1287-1295
Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum
Cervenka S; Backman L; Cselenyi Z; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2008;11(2):163-171
PET analysis of the 5-HT_2A receptor inverse agonist ACP-103 in human brain
Nordstrom A-L; Mansson M; Jovanovic H; Karlsson P; Halldin C; Farde L; Vanover KE; Hacksell U; Brann MR; Davis RE; Weiner DM
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2007;10(6):777-785
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram
Lundberg J; Christophersen JS; Petersen KB; Loft H; Halldin C; Farde L
Article: PSYCHOPHARMACOLOGY. 2007;195(3):425-433
A PET study on regional coexpression of 5-HT_1A receptors and 5-HTT in the human brain
Lundberg J; Borg J; Halldin C; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2007;27(2):369-377
Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [¹¹C]FLB 457 PET
Montgomery AJ; Asselin M-C; Farde L; Grasby PM
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2007;15(2):616-625
Synthesis of ¹¹C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET
Schou M; Pike VW; Sovago J; Gulyas B; Gallagher PT; Dobson DR; Walter MW; Rudyk H; Farde L; Halldin C
Article: PSYCHIATRY RESEARCH. 2006;148(2-3):165-173
Dopamine D₂ receptor binding in dirug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography
Talvik M; Nordstrom A-L; Okubo Y; Olsson H; Borg J; Halldin C; Farde L
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2006;49(11):1007-1019
Synthesis and PET evaluation of (R)-[S-methyl-¹¹C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters
Schou M; Pike VW; Varrone A; Gulyas B; Farde L; Halldin C
Article: NEUROIMAGE. 2006;32(4):1690-1708
A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [¹¹C]FLB 457 and [¹¹C]WAY 100635
Cselenyi Z; Olsson H; Halldin C; Gulyas B; Farde L
Article: PSYCHOPHARMACOLOGY. 2006;188(1):119-127
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion:: a PET study in nonhuman primate brain using (S,S)-[¹⁸F]FMeNER-D₂
Seneca N; Gulyas B; Varrone A; Schou M; Airaksinen A; Tauscher J; Vandenhende F; Kielbasa W; Farde L; Innis RB; Halldin C
Article: SYNAPSE. 2006;60(3):256-263
Measurement of serotonin transporter binding with PET and [¹¹C]MADAM:: A test-retest reproducibility study
Lundberg J; Halldin C; Farde L
Article: BRAIN. 2006;129(Pt 8):2017-2028
Support for dopaminergic hypoactivity in restless legs syndrome:: a PET study on D2-receptor binding
Cervenka S; Palhagen SE; Comley RA; Panagiotidis G; Cselenyi Z; Matthews JC; Lai RY; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006;33(6):657-668
Quantitative analyses of regional [¹¹C]PE2I binding to the dopamine transporter in the human brain:: a PET study
Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
Article: SYNAPSE. 2006;59(5):260-269
Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain:: A comparison of the agonist radioligand [^11C]MNPA and antagonist [¹¹C]raclopride
Seneca N; Finnema SJ; Farde L; Gulyás B; Wikström HV; Halldin C; Innis RB
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2006;9(2):247-255
Support for limited brain availability of tyrosine in patients with schizophrenia
Bjerkenstedt L; Farde L; Terenius L; Edman G; Venizelos N; Wiesel FA
Article: PSYCHOPHARMACOLOGY. 2006;185(3):389-394
Search for correlations between serotonin 5-HT_1A receptor expression and cognitive functions -: a strategy in translational psychopharmacology
Borg J; Andrée B; Lundberg J; Halldin C; Farde L
Article: PSYCHOPHARMACOLOGY. 2006;185(1):29-35
Clozapine binds preferentially to cortical D₁-like dopamine receptors in the primate brain:: a PET study
Chou YH; Halldin C; Farde L
Article: MOLECULAR IMAGING AND BIOLOGY. 2006;8(1):1-8
Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands:: [C-11]desipramine, [C-11]talopram and [C-11]talsupram
Schou M; Sóvágó J; Pike VW; Gulyás B; Bogeso KP; Farde L; Halldin C
Article: SYNAPSE. 2005;58(3):173-183
[¹¹C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET
Halldin C; Lundberg J; Sóvágó J; Gulyás B; Guilloteau D; Vercouillie J; Emond P; Chalon S; Tarkiainen J; Hiltunen J; Farde L
Article: BRAIN RESEARCH BULLETIN. 2005;67(3):219-224
Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [¹¹C]RGH-1756
Sóvágó J; Farde L; Halldin C; Schukin E; Schou M; Laszlovszky I; Kiss B; Gulyás B
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005;15(5):517-520
Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[¹⁸F]FMeNER-D₂
Schou M; Halldin C; Pike VW; Mozley PD; Dobson D; Innis RB; Farde L; Hall H
Article: JOURNAL OF NUCLEAR MEDICINE. 2005;46(9):1505-1515
Quantification of ¹¹C-MADAM binding to the serotonin transporter in the human brain
Lundberg J; Odano I; Olsson H; Halldin C; Farde L
Article: ARCHIVES OF NEUROLOGY. 2005;62(6):946-950
Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy
Meschaks A; Lindstrom P; Halldin C; Farde L; Savic I
Article: MOLECULAR IMAGING AND BIOLOGY. 2005;7(3):209-219
Two C-methyl derivatives of [¹¹C]WAY-100635 -: Effects of an amido α-methyl group on metabolism and brain 5-HT_1A receptor radioligand behavior in monkey
McCarron JA; Marchais-Oberwinkler S; Pike VW; Tarkiainen J; Halldin C; Sóvagó J; Gulyas BZ; Wikström HV; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2005;32(4):353-360
A preliminary PET evaluation of the new dopamine D₂ receptor agonist [¹¹C]MNPA in cynomolgus monkey
Finnema SJ; Seneca N; Farde L; Shchukin E; Sóvágó J; Gulyás B; Wikström HV; Innis RB; Neumeyer JL; Halldin C
Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2005;13(3):883-893
N-Oxide analogs of WAY-100635:: new high affinity 5-HT_1A receptor antagonists
Marchais-Oberwinkler S; Nowicki B; Pike VW; Halldin C; Sandell J; Chou YH; Gulyas B; Brennum LT; Farde L; Wikström HV
Article: PSYCHIATRY RESEARCH. 2005;138(1):1-12
The role of the striatal dopamine transporter in cognitive aging
Erixon-Lindroth N; Farde L; Wahlin TBR; Sovago J; Halldin C; Bäckman L
Article: NEUROCHEMISTRY INTERNATIONAL. 2004;45(5):773-781
Joint explorative analysis of neuroreceptor subsystems in the human brain:: application to receptor-transporter correlation using PET data
Cselényi Z; Lundberg J; Halldin C; Farde L; Gulyás B
Article: NEUROCHEMISTRY INTERNATIONAL. 2004;45(5):609-617
Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [¹¹C]RGH-1756 in the monkey brain
Sóvágó J; Farde L; Halldin C; Langer O; Laszlovszky I; Kiss B; Gulyás B
Article: PSYCHOPHARMACOLOGY. 2004;175(2):148-153
A cross-validation study on the relationship between central D₂ receptor occupancy and serum perphenazine concentration
Talvik M; Nordström AL; Larsen NE; Jucaite A; Cervenka S; Halldin C; Farde L
Article: SYNAPSE. 2004;53(2):57-67
PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain
Schou M; Halldin C; Sóvágó J; Pike VW; Hall H; Gulyás B; Mozley PD; Dobson D; Shchukin E; Innis RB; Farde L
Article: NEUROIMAGE. 2004;22(2):794-803
Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET
Olsson H; Halldin C; Farde L
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2004;161(6):1016-1022
Low dopamine D₂ receptor binding in subregions of the thalamus in schizophrenia
Yasuno F; Suhara T; Okubo Y; Sudo Y; Inoue M; Ichimiya T; Takano A; Nakayama K; Haildin C; Farde L
Article: NEUROLOGY. 2004;62(8):1343-1351
Limbic reductions of 5-HT_1A receptor binding in human temporal lobe epilepsy
Savic I; Lindström P; Gulyás B; Halldin C; Andrée B; Farde L
Article: JOURNAL OF NEURAL TRANSMISSION. 2004;111(4):537-545
Transcription factor AP-2β genotype, striatal dopamine D2 receptor density and cerebrospinal fluid monoamine metabolite concentrations in humans
Damberg M; Berggård C; Farde L; Sedvall GC; Jönsson EG
Article: NUCLEAR MEDICINE AND BIOLOGY. 2004;31(3):327-336
New α₁-adrenoceptor antagonists derived from the antipsychotic sertindole-carbon-11 labelling and pet examination of brain uptake in the cynomolgus monkey
Balle T; Halldin C; Andersen L; Alifrangis LH; Badolo L; Jensen KG; Chou YW; Andersen K; Perregaard J; Farde L
Article: MOLECULAR IMAGING AND BIOLOGY. 2004;6(1):17-26
The pyridinyl-6 position of WAY-100635 as a site for radiofluorination-effect on 5-HT_1A receptor radioligand behavior in vivo
McCarron JA; Pike VW; Halldin C; Sandell J; Sóvagó J; Gulyas BS; Cselényi Z; Wikström HV; Marchais-Oberwinkler S; Nowicki B; Dollé F; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2003;6(4):361-370
Decreased thalamic D₂/D₃ receptor binding in drug-naive patients with schizophrenia:: a PET study with [¹¹C]FLB 457
Talvik M; Nordström AL; Olsson H; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2003;30(11):1520-1528
Radioiodinated SB 207710 as a radioligand in vivo:: imaging of brain 5-HT₄ receptors with SPET
Pike VW; Halldin C; Nobuhara K; Hiltunen J; Mulligan RS; Swahn CG; Karlsson P; Olsson H; Hume SP; Hirani E; Whalley J; Pilowsky LS; Larsson S; Schnell PO; Ell PJ; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2003;30(7):707-714
Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[¹¹C]MeNER
Schou M; Halldin C; Sóvágó J; Pike VW; Gulyás B; Mozley PD; Johnson DP; Hall H; Innis RB; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2003;30(9):1220-1230
[¹¹C]PE2I:: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain
Halldin C; Erixon-Lindroth N; Pauli S; Chou YH; Okubo Y; Karlsson P; Lundkvist C; Olsson H; Guilloteau D; Emond P; Farde L
Article: AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS. 2003;120B(1):51-57
NURR1 promoter polymorphisms:: Parkinson's disease, schizophrenia, and personality traits
Carmine A; Buervenich S; Galter D; Jönsson EG; Sedvall GC; Farde L; Gustavsson JP; Bergman H; Chowdari KV; Nimgaonkar VL; Anvret M; Sydow O; Olson L
Article: BIOLOGICAL PSYCHIATRY. 2003;53(7):577-584
Association between a promoter dopamine D₂ receptor gene variant and the personality trait detachment
Jönsson EG; Cichon S; Gustavsson JP; Grünhage F; Forslund K; Mattila-Evenden M; Rylander G; Åsberg M; Farde L; Propping P; Nöthen MM
Article: PSYCHOPHARMACOLOGY. 2003;167(1):37-45
Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-lA receptors in the human brain
Andrée B; Hedman A; Thorberg SO; Nilsson D; Halldin C; Farde L
Article: PSYCHIATRIC GENETICS. 2003;13(1):23-28
Two NOTCH4 polymorphisms and their relation to schizophrenia susceptibility and different personality traits
Carmine A; Chheda MG; Jönsson EG; Sedvall GC; Farde L; Gustavsson JP; Bergman H; Anvret M; Buervenich S; Olson L
Article: PSYCHOPHARMACOLOGY. 2003;166(3):234-240
Occupancy of 5-HT_1A receptors by clozapine in the primate brain:: a PET study
Chou YH; Halldin C; Farde L
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2003;304(1):81-87
Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity
Chalon S; Tarkiainen J; Garreau L; Hall H; Emond P; Vercouillie J; Farde L; Dasse P; Varnas K; Besnard JC; Halldin C; Guilloteau D
Article: ACTA NEUROLOGICA SCANDINAVICA. 2002;106(6):325-332
PET studies on the brain uptake and regional distribution of [¹¹C] vinpocetine in human subjects
Gulyás B; Halldin C; Sandell J; Karlsson P; Sóvágó J; Kárpáti E; Kiss B; Vas A; Cselényi Z; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2002;29(7):753-759
Cerebral uptake of [ethyl-¹¹C]vinpocetine and 1-[¹¹C]ethanol in cynomolgous monkeys:: a comparative preclinical PET study
Gulyás B; Vas A; Halldin C; Sóvágó J; Sandell J; Olsson H; Fredriksson A; Stone-Elander S; Farde L
Article: NEUROIMAGE. 2002;17(1):47-60
Wavelet-aided parametric mapping of cerebral dopamine D₂ receptors using the high affinity PET radioligand [¹¹C]FLB 457
Cselényi Z; Olsson H; Farde L; Gulyás B
Article: NUCLEAR MEDICINE AND BIOLOGY. 2002;29(6):651-656
PET examination of [¹¹C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter
Sandell J; Halldin C; Sovago J; Chou YH; Gulyás B; Yu MX; Emond P; Någren K; Guilloteau D; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2002;29(8):1031-1038
Drug distribution in man:: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine
Gulyás B; Halldin C; Sóvágó J; Sandell J; Cselényi Z; Vas A; Kiss B; Kárpáti E; Farde L
Article: PSYCHOPHARMACOLOGY. 2002;162(1):37-41
Low striatal and extra-striatal D₂ receptor occupancy during treatment with the atypical antipsychotic sertindole
Nyberg S; Olsson H; Nilsson U; Maehlum E; Halldin C; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 2002;43(3):292-303
The PET radioligand [carbonyl-¹¹C]desmethyl-WAY-100635 binds to 5-HT_1A receptors and provides a higher radioactive signal than [carbonyl-¹¹C]WAY-100635 in the human brain
Andrée B; Halldin C; Pike VW; Gunn RN; Olsson H; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2002;29(1):39-45
PET-examination and metabolite evaluation in monkey of [¹¹C]NAD-299, a radioligand for visualisation of the 5-HT_1A receptor
Sandell J; Halldin C; Chou YH; Swahn CG; Thorberg SO; Farde L
Article: ARCHIVES OF GENERAL PSYCHIATRY. 2002;59(1):25-30
Decreased dopamine D₂ receptor binding in the anterior cingulate cortex in schizophrenia
Suhara T; Okubo Y; Yasuno F; Sudo Y; Inoue M; Ichimiya T; Nakashima Y; Nakayama K; Tanada S; Suzuki K; Halldin C; Farde L
Article: BIOLOGIA FUTURA. 2002;53(1-2):59-66
Autoradiographic evaluation of [¹¹C]vinpocetine binding in the human postmortem brain
Hall H; Varnäs K; Sandell J; Halldin C; Farde L; Vas A; Kárpáti E; Gulyás B
Article: NEUROIMAGE. 2001;14(4):936-945
Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - A simulation study based on experimental data
Olsson H; Farde L
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2001;158(6):926-930
No support for regional selectivity in clozapine-treated patients:: A PET study with [¹¹C]raclopride and [¹¹C]FLB 457
Talvik M; Nordström AL; Nyberg S; Olsson H; Halldin C; Farde L
Article: NEUROIMAGE. 2001;13(3):531-539
Error analysis for quantification of [¹¹C]FLB 457 binding to extrastriatal D₂ dopamine receptors in the human brain
Ito H; Sudo Y; Suhara T; Okubo Y; Halldin C; Farde L
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2001;158(2):308-311
Sex differences in extrastriatal dopamine D₂-like receptors in the human brain
Kaasinen V; Någren K; Hietala J; Farde L; Rinne JO
Article: NUCLEAR MEDICINE AND BIOLOGY. 2001;28(2):177-185
New halogenated [¹¹C]WAY analogues, [¹¹C]6FPWAY and [¹¹C]6BPWAY -: Radiosynthesis and assessment as radioligands for the study of brain 5-HT_1A receptors in living monkey
Sandell J; Halldin C; Pike VW; Chou YH; Varnäs K; Hall H; Marchais S; Nowicki B; Wikström HV; Swahn CG; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;28(1):13-24
SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP
Nobuhara K; Farde L; Halldin C; Karlsson P; Swahn CG; Olsson H; Bergström KA; Larsson SA; Schnell PO; McPherson DW; Savonen A; Hiltunen J; Sedvall G
Article: SYNAPSE. 2000;38(4):421-431
Autoradiographic localization of 5-HT_2A receptors in the human brain using L³H]M100907 and [¹¹C]M100907
Hall H; Farde L; Halldin C; Lundkvist C; Sedvall G
Article: SYNAPSE. 2000;38(2):138-143
Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study
Chou YH; Halldin C; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 2000;27(8):707-714
Carbon-11 PB-12:: An attempt to visualize the dopamine D₄ receptor in the primate brain with positron emission tomography
Langer O; Halldin C; Chou YH; Sandell J; Swahn CG; Någren K; Perrone R; Berardi F; Leopoldo M; Farde L
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2000;43(11):1069-1074
Radiochemical labelling of the dopamine D₃ receptor ligand RGH-1756
Langer O; Gulyás B; Sandell J; Laszlovszky I; Kiss B; Domány G; Acs T; Farde L; Halldin C
Article: NEUROBIOLOGY OF AGING. 2000;21(5):683-688
Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain
Kaasinen V; Vilkman H; Hietala J; Någren K; Helenius H; Olsson H; Farde L; Rinne JO
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2000;43(10):1033-1046
Synthesis of [¹¹C]2β-carbomethoxy-3β-(3′-iodo-4′-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography
Sandell J; Halldin C; Helfenbein J; Chou YH; Vercouillie J; Emond P; Swahn CG; Guilloteau D; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2000;3(3):203-214
A PET study of [¹¹C]β-CIT-FE binding to the dopamine transporter in the monkey and human brain
Farde L; Ginovart N; Halldin C; Chou YH; Olsson H; Swahn CG
Article: NEUROLOGY. 2000;54(7):1482-1487
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease
Kaasinen V; Någren K; Hietala J; Oikonen V; Vilkman H; Farde L; Halldin C; Rinne JO
Article: AMERICAN JOURNAL OF PSYCHIATRY. 2000;157(4):635-637
Age-related cognitive deficits mediated by changes in the striatal dopamine system
Bäckman L; Ginovart N; Dixon RA; Wahlin TBR; Wahlin Å; Halldin C; Farde L
Article: NEUROPSYCHOPHARMACOLOGY. 2000;22(4):422-429
PET-determination of robalzotan (NAD-299) induced 5-HT_1A receptor occupancy in the monkey brain
Farde L; Andrée B; Ginovart N; Halldin C; Thorberg SO
Article: PSYCHOPHARMACOLOGY. 2000;149(1):45-55
Z-IQNP:: a potential radioligand for SPECT imaging of muscarinic acetylcholine receptors in Alzheimer's disease
Nobuhara K; Halldin C; Hall H; Karlsson P; Farde L; Hiltunen J; McPherson DW; Savonen A; Bergström KA; Pauli S; Swahn CG; Larsson SA; Schnell PO; Sedvall G
Article: PSYCHOPHARMACOLOGY. 2000;148(4):400-403
High 5HT_2A receptor occupancy in M100907-treated schizophrenic patients
Talvik-Lotfi M; Nyberg S; Nordström AL; Ito H; Halldin C; Brunner F; Farde L
Article: NEUROIMAGE. 1999;10(6):666-674
PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [¹¹C]FLB 457
Okubo Y; Olsson H; Ito H; Lofti M; Suhara T; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1999;26(11):1482-1485
Iodine-123 labelled Z-(R,R)-IQNP:: a potential radioligand for visualization of M₁ and M₂ muscarinic acetylcholine receptors in Alzheimer's disease
Bergström KA; Halldin C; Savonen A; Okubo Y; Hiltunen J; Nobuhara K; Swahn CG; Karlsson P; McPherson D; Knapp FF; Larsson S; Schnell PO; Farde L
Article: JOURNAL OF NEUROIMAGING. 1999;9(4):217-222
Brain uptake and plasma metabolism of [¹¹C]vinpocetine:: A preliminary PET study in a cynomolgus monkey
Gulyás B; Halldin C; Karlsson P; Chou YH; Swahn CG; Bönöck P; Paróczai M; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 1999;19(10):1164-1173
Quantification of [¹¹C]FLB 457 binding to extrastriatal dopamine receptors in the human brain
Olsson H; Halldin C; Swahn CG; Farde L
Article: PSYCHOPHARMACOLOGY. 1999;146(2):220-227
A PET study of D₁-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain
Chou YH; Karlsson P; Halldin C; Olsson H; Farde L
Article: ORVOSI HETILAP. 1999;140(30):1687-1691
[Cerebral uptake and metabolism of (11C) Vinpocetine in monkeys: PET studies].
Gulyás B; Halldin C; Karlsson P; Chou YH; Swahn CG; Bönöczk P; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(5):509-518
Carbon-11 epidepride:: A suitable radioligand for PET investigation of striatal and extrastriatal dopamine D₂ receptors
Langer O; Halldin C; Dollé F; Swahn CG; Olsson H; Karlsson P; Hall H; Sandell J; Lundkvist C; Vaufrey F; Loc'h C; Crouzel C; Mazière B; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(5):501-507
Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter
Lundkvist C; Loc'h C; Halldin C; Bottlaender M; Ottaviani M; Coulon C; Fuseau C; Mathis C; Farde L; Mazière B
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(5):491-499
PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter
Helfenbein J; Sandell J; Halldin C; Chalon S; Emond P; Okubo Y; Chou YH; Frangin Y; Douziech L; Gareau L; Swahn CG; Besnard JC; Farde L; Guilloteau D
Article: PSYCHOPHARMACOLOGY. 1999;144(3):303-305
Pindolol binding to 5-HT_1A receptors in the human brain confirmed with positron emission tomography
Andrée B; Thorberg SO; Halldin C; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 1999;2(2):73-82
Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET
Suhara T; Sudo Y; Okauchi T; Maeda J; Kawabe K; Suzuki K; Okubo Y; Nakashima Y; Ito H; Tanada S; Halldin C; Farde L
Article: MOLECULAR PSYCHIATRY. 1999;4(3):290-296
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers
Jönsson EG; Nöthen MM; Grünhage F; Farde L; Nakashima Y; Propping P; Sedvall GC
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(4):343-350
Different brain radioactivity curves in a PET study with [¹¹C]β-CIT labelled in two different positions
Lundkvist C; Halldin C; Swahn CG; Ginovart N; Farde L
Article: NEUROIMAGE. 1999;9(2):235-242
Mapping of central D₂ dopamine receptors in man using [¹¹C]raclopride:: PET with anatomic standardization technique
Ito H; Okubo Y; Halldin C; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1999;26(2):159-164
Radiosynthesis and autoradiographic evaluation of [¹¹C]NAD-299, a radioligand for visualization of the 5-HT_1A receptor
Sandell J; Halldin C; Hall H; Thorberg SO; Werner T; Sohn D; Sedvall G; Farde L
Article: SYNAPSE. 1999;31(2):154-162
Changes in striatal D₂-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates
Ginovart N; Farde L; Halldin C; Swahn CG
Article: JOURNAL OF NUCLEAR MEDICINE. 1999;40(1):102-109
Localization of 5-HT_1A receptors in the living human brain using [carbonyl-¹¹C]WAY-100635:: PET with anatomic standardization technique
Ito H; Halldin C; Farde L
Article: NEUROIMAGE. 1999;9(1):108-116
Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [¹²⁵I]PE2I
Hall H; Halldin C; Guilloteau D; Chalon S; Emond P; Besnard JC; Farde L; Sedvall G
Article: JOURNAL OF NUCLEAR MEDICINE. 1998;39(12):2061-2068
Carbon-11-NNC 112:: A radioligand for PET examination of striatal and neocortical D₁-dopamine receptors
Halldin C; Foged C; Chou YH; Karlsson P; Swahn CG; Sandell J; Sedvall G; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 1998;1(2):95-101
D₂- and 5-HT₂ receptor occupancy in high-dose neuroleptic-treated patients
Nyberg S; Dencker SJ; Malm U; Dahl ML; Svenson JO; Halldin C; Naskashima Y; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 1998;39(11):1965-1971
Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man
Farde L; Ito H; Swahn CG; Pike VW; Halldin C
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 1998;18(9):941-950
Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [¹¹C]raclopride binding
Ito H; Hietala J; Blomqvist G; Halldin C; Farde L
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1998;18(4):317-323
Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain
Andrée B; Nyberg S; Ito H; Ginovart N; Brunner F; Jaquet F; Halldin C; Farde L
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1998;18(4):305-310
Plasma prolactin and central D₂ receptor occupancy in antipsychotic drug-treated patients
Nordström AL; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(5):503-508
[¹¹C]NNC 22-0215, a metabolically stable dopamine D₁ radioligand for PET
Foged C; Halldin C; Swahn CG; Ginovart N; Karlsson P; Lundkvist C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1998;25(5):531-534
Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
Kuikka JT; Baulieu JL; Hiltunen J; Halldin C; Bergström KA; Farde L; Emond P; Chalon S; Yu MX; Nikula T; Laitinen T; Karhu J; Tupala E; Hallikainen T; Kolehmainen V; Mauclaire L; Maziere B; Tiihonen J; Guilloteau D
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(4):405-409
Toxicity, mutagenicity, and behavioral effects of β-CIT, a ligand for dopamine transporter exploration by SPECT
Emond P; Farde L; Chalon S; Belzung C; Mauclaire V; Chiron JP; Halldin C; Besnard JC; Guilloteau D
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1998;25(4):338-346
[carbonyl-¹¹C]desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT_1A receptors in vitro and in vivo
Pike VW; Halldin C; McCarron JA; Lundkvist C; Hirani E; Olsson H; Hume SP; Karlsson P; Osman S; Swahn CG; Hall H; Wikström H; Mensonidas M; Poole KG; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(3):215-223
Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT_1A receptor radioligand, [carbonyl-¹¹C]WAY-100635 -: Explanation of high signal contrast in PET and an aid to biomathematical modelling
Osman S; Lundkvist C; Pike VW; Halldin C; McCarron JA; Swahn CG; Farde L; Ginovart N; Luthra SK; Gunn RN; Bench CJ; Sargent PA; Grasby PM
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(3):209-214
Evaluation and metabolite studies of ¹²⁵I- and ¹²³I-labelled E-(R,R)-IQNP:: Potential radioligands for visualization of M₁ muscarinic acetylcholine receptors in brain
Bergstrom KA; Halldin C; Hiltunen J; Swahn CG; Ito H; Ginovart N; Hall H; McPherson DW; Knapp FFR; Larsson S; Schnell PO; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 1998;39(1):208-214
PET imaging of central 5-HT_2A receptors with carbon-11-MDL 100,907
Ito H; Nyberg S; Halldin C; Lundkvist C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;25(1):19-23
Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography
Hiltunen J; Åkerman KK; Kuikka JT; Bergström KA; Halldin C; Nikula T; Räsänen P; Tiihonen J; Vauhkonen M; Karhu J; Kupila J; Länsimies E; Farde L
Article: BRAIN. 1997;120:2207-2217
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes
Bäckman L; Robins-Wahlin TB; Lundin A; Ginovart N; Farde L
Article: PSYCHOPHARMACOLOGY. 1997;133(4):396-404
A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients
Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;24(10):1261-1267
Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET)
Foged C; Halldin C; Loch C; Maziere B; Pauli S; Maziere M; Hansen HC; Suhara T; Swahn CG; Karlsson P; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1997;24(7):629-634
[I-125]beta-CIT-FE and [I-125]beta-CIT-FP are superior to [I-125]beta-CIT for dopamine transporter visualization: Autoradiographic evaluation in the human brain
Gunther I; Hall H; Halldin C; Swahn CG; Farde L; Sedvall G
Article: NUCLEAR MEDICINE AND BIOLOGY. 1997;24(7):621-627
[F-18]beta-CIT-FP is superior to [C-11]beta-CIT-FP for quantitation of the dopamine transporter
Lundkvist C; Halldin C; Ginovart N; Swahn CG; Farde L
Article: ARCHIVES OF GENERAL PSYCHIATRY. 1997;54(10):953-958
Delayed normalization of central D-2 dopamine receptor availability after discontinuation of haloperidol decanoate - Preliminary findings
Nyberg S; Farde L; Halldin C
Article: PSYCHOPHARMACOLOGY. 1997;133(2):196-202
PET-characterization of [carbonyl-C-11]WAY-100635 binding to 5-HT1A receptors in the primate brain
Farde L; Ginovart N; Ito H; Lundkvist C; Pike VW; McCarron JA; Halldin C
Article: NUCLEAR MEDICINE AND BIOLOGY. 1997;24(5):389-393
Autoradiographic comparison of [I-125]epidepride and [I-125]NCQ 298 binding to human brain extrastriated dopamine receptors
Hall H; Halldin C; Jerning E; Osterlund M; Farde L; Sedvall G
Article: PSYCHOPHARMACOLOGY. 1997;131(4):339-345
Central 5-HT2A and D-2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men
Andree B; Halldin C; VrijmoeddeVries M; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;24(6):596-601
In vitro and in vive characterisation of nor-beta-CIT: A potential radioligand for visualisation of the serotonin transporter in the brain
Bergstrom KA; Halldin C; Hall H; Lundkvist C; Ginovart N; Swahn CG; Farde L
Article: SYNAPSE. 1997;25(4):321-325
Effect of reserpine-induced depletion of synaptic dopamine on [C-11]raclopride binding to D-2-dopamine receptors in the monkey brain
Ginovart N; Farde L; Halldin C; Swahn CG
Article: BRAIN. 1997;120:503-514
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease
Ginovart N; Lundin A; Farde L; Halldin C; Backman L; Swahn CG; Pauli S; Sedvall G
Article: DRUG DEVELOPMENT RESEARCH. 1997;40(2):158-170
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
Bymaster FP; Whitesitt CA; Shannon HE; DeLapp N; Ward JS; Calligaro DO; Shipley LA; BuelkeSam JL; Bodick NC; Farde L; Sheardown MJ; Olesen PH; Hansen KT; Suzdak PD; Swedberg MDB; Sauerberg P; Mitch CH
Article: BRAIN RESEARCH. 1997;745(1-2):96-108
Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [H-3]WAY-100635 and [C-11]WAY-100635
Hall H; Lundkvist C; Halldin C; Farde L; Pike VW; McCarron JA; Fletcher A; Cliffe IA; Barf T; Wikstrom H; Sedvall G
Article: NEUROPSYCHOPHARMACOLOGY. 1997;16(1):1-7
A PET study of 5-HT2 and D-2 dopamine receptor occupancy induced by olanzapine in healthy subjects
Nyberg S; Farde L; Halldin C
Article: PSYCHOPHARMACOLOGY. 1996;128(3):240-247
Autoradiographic localisation of D-3-dopamine receptors in the human brain using the selective D-3-dopamine receptor agonist (+)-[H-3]PD 128907
Hall H; Halldin C; Dijkstra D; Wikstrom H; Wise LD; Pugsley TA; Sokoloff P; Pauli S; Farde L; Sedvall G
Article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 1996;11(6):483-490
Characterization of C-11 or I-123 labelled beta-CIT-FP and beta-CIT-FE metabolism measured in monkey and human plasma. Identification of two labelled metabolites with HPLC
Bergstrom KA; Halldin C; Lundkvist C; Swahn CG; Akerman KK; Kuikka JT; Hiltunen J; Tiihonen J; Lansimies E; Neumeyer JL; Farde L
Article: PSYCHIATRY RESEARCH. 1996;67(3):163-171
Test-retest reliability of central [C-11]raclopride binding at high D-2 receptor occupancy. A PET study in haloperidol-treated patients
Nyberg S; Farde L; Halldin C
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(6):837-844
C-11- and Br-76-labelled NNC 22-0010, selective dopamine D-1 receptor radioligands for PET
Foged C; Halldin C; Loch C; Maziere B; Karlsson P; Maziere M; Swahn CG; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(6):813-819
Preparation of [Br-76]FLB 457 and [Br-76]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET
Loch C; Halldin C; Bottlaender M; Swahn CG; Moresco RM; Maziere M; Farde L; Maziere B
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(5):627-634
Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-C-11]WAY-100635, in monkey and human plasma by HPLC: Comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET
Osman S; Lundkvist C; Pike VW; Halldin C; McCarron JA; Swahn CG; Ginovart N; Luthra SK; Bench CJ; Grasby PM; Wikstrom H; Barf T; Cliffe IA; Fletcher A; Farde L
Article: DEMENTIA. 1996;7(4):187-195
PET study of the M(1)-agonists [C-11]xanomeline and [C-11]butylthio-TZTP in monkey and man
Farde L; Suhara T; Halldin C; Nyback H; Nakashima Y; Swahn CG; Karlsson P; Ginovart N; Bymaster FP; Shannon HE; Foged C; Suzdak PD; Sauerberg P
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1996;23(7):798-803
Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241)
Kuikka JT; Hiltunen J; Foged C; Bergstrom KA; Halldin C; Akerman K; Tiihonen J; Farde L
Article: TRENDS IN NEUROSCIENCES. 1996;19(6):211-214
The advantage of using positron emission tomography in drug research
Farde L
Article: SYNAPSE. 1996;23(2):115-123
Autoradiographic localization of extrastriatal D-2-dopamine receptors in the human brain using [I-125]epidepride
Hall H; Farde L; Halldin C; Hurd YL; Pauli S; Sedvall G
Article: SYNAPSE. 1996;22(4):386-390
[C-11] beta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography
Halldin C; Farde L; Lundkvist C; Ginovart N; Nakashima Y; Karlsson P; Swahn CG
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(3):221-227
[C-11]metaraminol, a false neurotransmitter: Preparation, metabolite studies and positron emission tomography examination in monkey
Nagren K; Halldin C; Swahn CG; Suhara T; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(3):201-209
Development of I-123-labelled NNC 13-8241 as a radioligand for SPECT visualization of benzodiazepine receptor binding
Foged C; Halldin C; Hiltunen J; Braestrup C; Thomsen C; Hansen HC; Suhara T; Pauli S; Swahn CG; Karlsson P; Larsson S; Farde L
Article: ANNALS OF NUCLEAR MEDICINE. 1996;10(1):85-88
Effects of cocaine on [11C]norepinephrine and [11C] beta-CIT uptake in the primate peripheral organs measured by PET.
Suhara T; Farde L; Halldin C; Någren K; Karlsson P
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):1053-1056
PET EXAMINATION OF THE MONKEY HEART WITH HIGH SPECIFIC RADIOACTIVITY [C-11] NOREPINEPHRINE AND [C-11] METARAMINOL
FARDE L; HALLDIN C; NAGREN K; KARLSSON P; SWAHN CG; SUHARA T
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):1045-1048
AN HPLC-METHOD FOR DETERMINATION OF LIGAND METABOLISM DURING PET STUDIES WITH [C-11] METARAMINOL AND [C-11] NOREPINEPHRINE
SWAHN CG; HALLDIN C; NAGREN K; FARDE L
Article: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1995;10(4):221-227
CENTRAL D-2 RECEPTOR OCCUPANCY AND EFFECTS OF ZUCLOPENTHIXOL ACETATE IN HUMANS
NYBERG S; FARDE L; BARTFAI A; HALLDIN C
Article: AMERICAN JOURNAL OF PSYCHIATRY. 1995;152(10):1444-1449
D-1, D-2, AND 5-HT2 RECEPTOR OCCUPANCY IN RELATION TO CLOZAPINE SERUM CONCENTRATION - A PET STUDY OF SCHIZOPHRENIC-PATIENTS
NORDSTROM AL; FARDE L; NYBERG S; KARLSSON P; HALLDIN C; SEDVALL G
Article: PSYCHOPHARMACOLOGY. 1995;121(3):309-316
LACK OF APPARENT ANTIPSYCHOTIC EFFECT OF THE D-1-DOPAMINE RECEPTOR ANTAGONIST SCH39166 IN ACUTELY ILL SCHIZOPHRENIC-PATIENTS
KARLSSON P; SMITH L; FARDE L; HARNRYD C; SEDVALL G; WIESEL FA
Article: PSYCHOPHARMACOLOGY. 1995;121(3):300-308
EVALUATION OF SCH-39166 AS PET LIGAND FOR CENTRAL D-1 DOPAMINE-RECEPTOR BINDING AND OCCUPANCY IN MAN
KARLSSON P; SEDVALL G; HALLDIN C; SWAHN CG; FARDE L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(7):905-913
[O-METHYL-C-11]BETA-CIT-FP, A POTENTIAL RADIOLIGAND FOR QUANTITATION OF THE DOPAMINE TRANSPORTER - PREPARATION, AUTORADIOGRAPHY, METABOLITE STUDIES, AND POSITRON EMISSION TOMOGRAPHY EXAMINATIONS
LUNDKVIST C; HALLDIN C; SWAHN CG; HALL H; KARLSSON P; NAKASHIMA Y; WANG SY; MILIUS RA; NEUMEYER JL; FARDE L
Article: LANCET. 1995;346(8977):743-749
CHEMICAL BRAIN ANATOMY IN SCHIZOPHRENIA
SEDVALL G; FARDE L
Article: PSYCHIATRY RESEARCH. 1995;61(2):67-83
NO ELEVATED D-2 DOPAMINE-RECEPTORS IN NEUROLEPTIC-NAIVE SCHIZOPHRENIC-PATIENTS REVEALED BY POSITRON EMISSION TOMOGRAPHY AND [C-11] N-METHYLSPIPERONE
NORDSTROM AL; FARDE L; ERIKSSON L; HALLDIN C
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(6):711-717
SYNTHESIS AND BINDING-PROPERTIES OF [H-3]NNC-12-0781, A NEW RADIOLIGAND FOR THE DOPAMINE REUPTAKE SYSTEM
MULLER L; HALL H; HALLDIN C; FARDE L; HOHLWEG R; SUZDAK PD; NIELSEN EB; FOGED C
Article: SYNAPSE. 1995;20(3):200-208
VARIABILITY IN D-2-DOPAMINE RECEPTOR DENSITY AND AFFINITY - A PET STUDY WITH [C-11] RACLOPRIDE IN MAN
FARDE L; HALL H; PAULI S; HALLDIN C
Article: JOURNAL OF NUCLEAR MEDICINE. 1995;36(7):1275-1281
CARBON-11-FLB-457 - A RADIOLIGAND FOR EXTRASTRIATAL D2 DOPAMINE-RECEPTORS
HALLDIN C; FARDE L; HOGBERG T; MOHELL N; HALL H; SUHARA T; KARLSSON P; NAKASHIMA Y; SWAHN CG
Article: PSYCHOPHARMACOLOGY. 1995;119(1):1-8
ORAL-ADMINISTRATION OF NNC-756 - A PLACEBO-CONTROLLED PET STUDY OF D-1-DOPAMINE RECEPTOR OCCUPANCY AND PHARMACODYNAMICS IN MAN
KARLSSON P; FARDE L; HALLDIN C; SEDVALL G; YNDDAL L; SLOTHNIELSEN M
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 1995;36(4):385-392
SYNTHESIS OF 2-BETA-CARBOMETHOXY-3-BETA-(4-[BR-76]BROMOPHENYL)TROPANE ([BR-76]BETA-CBT), A PET TRACER FOR IN-VIVO IMAGING OF THE DOPAMINE UPTAKE SITES
LOCH C; MULLER L; OTTAVIANI M; HALLDIN C; FARDE L; MAZIERE B
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1995;5(1):19-25
EFFECT OF CLOZAPINE AND RISPERIDONE ON 5-HT2 AND D-2-DOPAMINE RECEPTOR-BINDING IN THE POSTMORTEM HUMAN BRAIN - AN AUTORADIOGRAPHIC STUDY
HALL H; HALLDIN C; NYBERG S; FARDE L; SEDVALL G
Article: ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES. 1995;32(1):22-29
RECENT DEVELOPMENTS IN PET SCAN IMAGING OF NEURORECEPTORS IN SCHIZOPHRENIA
SEDVALL G; PAULI S; FARDE L; KARLSSON P; NYBERG S; NORDSTROM AL
Article: CLINICAL NEUROSCIENCE. 1995;3(2):112-121
UTILIZATION OF RADIOLIGANDS IN SCHIZOPHRENIA RESEARCH
SEDVALL G; FARDE L; HALL H; HALLDIN C; KARLSSON P; NORDSTROM AL; NYBERG S; PAULI S
Visa fler

Alla övriga publikationer

Letter: MOVEMENT DISORDERS. 2022;37(8):1776-1778
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy
Rinne JO; Jucaite A; Cselenyi Z; Farde L
Letter: NEUROIMAGE. 2020;207:116371
In response to the letter "[¹¹C]raclopride and extrastriatal binding to D2/3 receptors"
Svensson JE; Schain M; Plaven-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
Letter: BIOLOGICAL PSYCHIATRY. 2019;85(7):e35-e39
Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?
van Erp TGM; Walton E; Hibar DP; Schmaal L; Jiang W; Glahn DC; Pearlson GD; Yao N; Fukunaga M; Hashimoto R; Okada N; Yamamori H; Clark VP; Mueller BA; de Zwarte SMC; Ophoff RA; van Haren NEM; Andreassen OA; Gurholt TP; Gruber O; Kraemer B; Richter A; Calhoun VD; Crespo-Facorro B; Roiz-Santianez R; Tordesillas-Gutierrez D; Loughland C; Catts S; Fullerton JM; Green MJ; Henskens F; Jablensky A; Mowry BJ; Pantelis C; Quide Y; Schall U; Scott RJ; Cairns MJ; Seal M; Tooney PA; Rasser PE; Cooper G; Weickert CS; Weickert TW; Hong E; Kochunov P; Gur RE; Gur RC; Ford JM; Macciardi F; Mathalon DH; Potkin SG; Preda A; Fan F; Ehrlich S; King MD; De Haan L; Veltman DJ; Assogna F; Banaj N; de Rossi P; Iorio M; Piras F; Spalletta G; Pomarol-Clotet E; Kelly S; Ciufolini S; Radua J; Murray R; Marques TR; Simmons A; Borgwardt S; Schoenborn-Harrisberger F; Riecher-Roessler A; Smieskova R; Alpert KI; Bertolino A; Bonvino A; Di Giorgio A; Neilson E; Mayer AR; Yun J-Y; Cannon DM; Lebedeva I; Tomyshev AS; Akhadov T; Kaleda V; Fatouros-Bergman H; Flyckt L; Rosa PGP; Serpa MH; Zanetti MV; Hoschl C; Skoch A; Spaniel F; Tomecek D; McIntosh AM; Whalley HC; Knoechel C; Oertel-Knoechel V; Howells FM; Stein DJ; Temmingh HS; Uhlmann A; Lopez-Jaramillo C; Dima D; Faskowitz JI; Gutman BA; Jahanshad N; Thompson PM; Turner JA; Farde L; Flyckt L; Fatouros-Bergman H; Cervenka S; Collste K; Victorsson P; Engberg G; Erhardt S; Schwieler L; Malmqvist A; Hedberg M; Orhan F; Piehl F; Agartz I
Review: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES. 2018;373(1744):20170156
Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders
Farde L; Plaven-Sigray P; Borg J; Cervenka S
Review: PSYCHOPHARMACOLOGY. 2015;232(21-22):4129-4157
Application of cross-species PET imaging to assess neurotransmitter release in brain
Finnema SJ; Scheinin M; Shahid M; Lehto J; Borroni E; Bang-Andersen B; Sallinen J; Wong E; Farde L; Halldin C; Grimwood S
Review: JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS. 2013;40(3):267-279
Modeling of PET data in CNS drug discovery and development
Varnas K; Varrone A; Farde L
Review: CNS NEUROSCIENCE & THERAPEUTICS. 2011;17(2):97-103
Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia
Nord M; Farde L
Meeting abstract: NEUROIMAGE. 2010;52:S55
Confirmation of fenfluramine effect on 5-HT1B binding of [11C]AZ10419369 using an equilibrium approach
Finnema SJ; Varrone A; Hwang TJ; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2010;52:S126
[¹⁸F]AZD4694-A new PET radioligand for sensitive detection of β-amyloid deposits
Jureus A; Swahn B-M; Sandell J; Jeppsson F; Neelissen JAM; Halldin C; Johnstrom P; Schou M; Cselenyi Z; Farde L; Svensson SPS
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S299-S300
In vivo assessment of changes in serotonin release in the non-human primate brain using PET and [11C]AZ10419369
Finnema SJ; Varrone A; Hwang TJ; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2010;52:S164-S165
Quantification of serotonin transporter availability with [11C]MADAM - A comparison between the ECAT HRRT and HR systems
Nilsson MS; Toth M; Cseleny Z; Karlsson P; Halldin C; Farde L; Varrone A
Meeting abstract: NEUROIMAGE. 2010;52:S142
Quantification and wavelet-aided parametric imaging of cerebral amyloid using the HRRT PET-system and [18F]AZD4694
Cselenyi Z; Jonhagen ME; Forsberg A; Halldin C; Julin P; Schou M; Johnstroem P; Varnas K; Svensson S; Farde L
Meeting abstract: NEUROIMAGE. 2010;52:S61-S62
Amphetamine decreases binding of the novel alpha2C-adrenoreceptor radioligand [11C]ORM-13070 in monkey brain
Finnema SJ; Varnas K; Stepanov V; Varrone A; Gulyas B; Arponen E; Helin S; Solin O; Haaparanta M; Sallinen J; Ingman K; Scheinin M; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2010;52:S122
The novel mGluR5 radioligand [¹¹C]AZ11696415: Palladium mediated ¹¹C-cyanation and initial in vivo characterization in the cynomolgus monkey brain using positron emission tomography (PET)
Andersson J; Seneca N; Truong P; Wensbo D; McLeod D; Raboisson P; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2010;52:S95
Regional distribution of high and low affinity states of dopamine D2/3 receptor binding in humans: A PET study using [11C]MNPA and [11C]raclopride
Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Fujie S; Sasaki T; Nakayama K; Halldin C; Farde L; Suhara T
Published conference paper: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36(10):1639-1650
Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT
Varrone A; Sjoholm N; Eriksson L; Gulyas B; Halldin C; Farde L
Published conference paper: NEUROPSYCHOLOGIA. 2009;47(11):2299-2304
Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning
MacDonald SWS; Cervenka S; Farde L; Nyberg L; Backman L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S7-S8
Limbic dopamine D2-receptor binding and social desirability
Cervenka S; Halldin C; Farde L
Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2006;27(6):310-316
Using positron emission tomography to facilitate CNS drug development
Lee C-M; Farde L
Meeting abstract: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;79(2):P74
Pharmacokinetics and dopamine D₂ and serotonin 5-HT_2A receptor occupancy of paliperidone in healthy subjects:: Two open-label, single-dose studies.
Karlsson P; Dencker E; Nyberg S; Mannaert E; Boom S; Talluri K; Rossenu S; Eriksson B; Eerdekens M; Farde L
Review: NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. 2006;30(6):791-807
The correlative triad among aging, dopamine, and cognition: Current status and future prospects
Backman L; Nyberg L; Lindenberger U; Li S-C; Farde L
Meeting abstract: NEUROIMAGE. 2006;31:T86
A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635
Cselenyi Z; Olsson H; Halldin C; Gulyas B; Farde L
Meeting abstract: NEUROIMAGE. 2006;31:T120
Dopamine D2/D3 receptor occupancy of apomorphine evaluated with the agonist radioligand [11C]MNPA and the antagonist radioligand [11C]Raclopride.: A PET evaluation in the non-human primate brain
Finnema S; Bang-Andersen B; Farde L; Gulyas B; Wikstrom HV; Halldin C
Meeting abstract: NEUROIMAGE. 2006;31:T114
PET evaluation of the partial dopamine D1 receptor agonist radioligands R- and S-[11C]N-methyl-NNC 01-0259
Finnema S; Bang-Andersen B; Farde L; Jorgensen M; Gulyas B; Foged C; Wikstrom HV; Halldin C
Meeting abstract: NEUROIMAGE. 2006;31:T88
Comparisons of central benzodiazepine receptor mapping tracers, [18F]Flumazenil and [11C]Flumazenil presentation
Odano I; Farde L; Savic I; Ciumas C; Krasikova R; Airaksinen A; Karlsson P; Pauli S; Halldin C
Meeting abstract: NEUROIMAGE. 2006;31:T87
Dopamine transporter binding corrected for tissue heterogeneity and partial volume effect using [11C]PE2I and PET
Odano I; Jucaite A; Olsson H; Karlsson P; Pauli S; Halldin C; Farde L
Meeting abstract: NEUROIMAGE. 2006;31:T85
Increasing the accuracy of in vivo quantification of dopamine-D2/D3 receptor binding in the human brain by partial volume effect correction
Sovago J; Farde L; Cervenka S; Halldin C; Gulyas B
Meeting abstract: NEUROIMAGE. 2006;31:T48
Synthesis of ¹¹C-labeled (S,S)-CFMME and (R)-OHDMI and their evaluation as candidate radioligands for imaging norepinephrine transporters with PET
Schou M; Pike VW; Sovago J; Gulyas B; Gallagher P; Dobson D; Walter MW; Rudyk H; Farde L; Halldin C
Meeting abstract: NEUROIMAGE. 2006;31:T28
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion:: A PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2
Seneca N; Gulyas B; Varrone A; Schou M; Tauscher J; Vandenhende F; Kielbasa W; Farde L; Innis RB; Halldin C
Review: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(4):615-629
QTc interval prolongation and antipsychotic drug treatments:: focus on sertindole
Lindström E; Farde L; Eberhard J; Haverkamp W
Published conference paper: JOURNAL OF THE NEUROLOGICAL SCIENCES. 2005;229:219-223
[¹¹C]Vinpocetine:: a prospective peripheral benzodiazepine receptor ligand for primate PET studies
Gulyás B; Halldin C; Vas A; Banati RB; Shchukin E; Finnema S; Tarkainen J; Tihanyi K; Szilágyi G; Farde L
Letter: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(1):141-142
Half-life of receptor occupancy - a meaningless concept
Olsson H; Farde L
Published conference paper: BIOLOGICAL PSYCHIATRY. 2005;57(3):229-238
Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity
Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
Review: ERNST SCHERING RESEARCH FOUNDATION WORKSHOP. 2004;48(48):95-109
PET for drug development
Halldin C; Gulyás B; Farde L
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 2003;160(11):1965-1969
The serotonin system and spiritual experiences
Borg J; Andrée B; Soderstrom H; Farde L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13:S330
PET examinations or thalamic D2 receptors in schizophrenic patients
Talvik M; Nordström AL; Olsson H; Halldin C; Farde L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13:S109-S110
Is dopamine a variable in PET-studies on drug induced receptor occupancy?
Farde L
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 2002;159(5):761-767
PET study of D₁ dopamine receptor binding in neuroleptic-naive patients with schizophrenia
Karlsson P; Farde L; Halldin C; Sedvall G
Review: CURRENT PHARMACEUTICAL DESIGN. 2001;7(18):1907-1929
PET studies with carbon-11 radioligands in neuropsychopharmacological drug development
Halldin C; Gulyás B; Farde L
Review: SCANDINAVIAN JOURNAL OF PSYCHOLOGY. 2001;42(3):287-296
Dopamine and cognitive functioning:: Brain imaging findings in Huntington's disease and normal aging
Bäckman L; Farde L
Review: QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;45(2):139-152
Brain radioligands -: State of the art and new trends
Halldin C; Gulyás B; Langer O; Farde L
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 2000;27(5):515-521
Use of PET and the radioligand [Carbonyl-¹¹C]WAY-100635 in psychotropic drug development
Andrée B; Halldin C; Thorberg SO; Sandell J; Farde L
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 2000;27(5):449-455
Radioligands for the study of brain 5-HT_1A receptors in vivo -: Development of some new analogues of WAY
Pike VW; Halldin C; Wikström H; Marchais S; McCarron JA; Sandell J; Nowicki B; Swahn CG; Osman S; Hume SP; Constantinou M; Andrée B; Farde L
Editorial comment: PSYCHOPHARMACOLOGY. 2000;148(1):22-23
Non-equipotent doses partly explain differences among antipsychotics - implications of PET studies
Nyberg S; Farde L
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 1999;156(6):869-875
Suggested minimal effective dose of risperidone based on PET-measured D₂ and 5-HT_2A receptor occupancy in schizophrenic patients
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(8):715-719
Whole hemisphere autoradiography of the postmortem human brain
Hall H; Halldin C; Farde L; Sedvall G
Published conference paper: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1998;13:S15-S20
Implications of brain imaging for the management of schizophrenia
Nyberg S; Nilsson U; Okubo Y; Halldin C; Farde L
Letter: ARCHIVES OF GENERAL PSYCHIATRY. 1998;55(3):283-284
Positron emission tomography finding of a high striatal D₂ receptor occupancy in olanzapine-treated patients
Nordström AL; Nyberg S; Olsson H; Farde L
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1998;29(1-2):165
D2-density, personality traits, and negative symptoms of schizophrenia
Farde L
Published conference paper: SCHIZOPHRENIA RESEARCH. 1997;28(2-3):157-162
Brain imaging of schizophrenia - the dopamine hypothesis
Farde L
Editorial comment: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1997;94(7):2787-2788
Imaging the living human brain: Magnetic resonance imaging and positron emission tomography
Volkow ND; Rosen B; Farde L
Letter: NATURE. 1997;385(6617):590
D2 dopamine receptors and personality traits
Farde L; Gustavsson JP; Jonsson E
Editorial comment: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1997;12:S47-S48
How can we improve compliance in schizophrenia? Papers from a satellite symposium to the XXth congress of the Collegium Internationale Neuro-Psychopharmacologicum, Melbourne, Australia, 24 June 1996 - Conclusions
Farde L
Published conference paper: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1997;12:S3-S7
D-2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: A pilot study with sertindole in healthy subjects
Farde L; Mack RJ; Nyberg S; Halldin C
Editorial comment: JOURNAL OF PSYCHOPHARMACOLOGY. 1997;11(1):13-14
The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed
Nyberg S; Farde L
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1997;24(1-2):178-179
D-1-dopamine receptors in schizophrenia examined by PET
Karlsson P; Farde L; Halldin C; Sedvall G
Letter: PSYCHIATRY RESEARCH-NEUROIMAGING. 1996;67(2):161-162
In schizophrenia, some dopamine D-2-like receptors are still elevated - Reply
Nordstrom AL; Farde L
Published conference paper: BRITISH JOURNAL OF PSYCHIATRY. 1996;168(29):40-44
Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs - Review of D-2 and 5-HT2 receptor occupancy studies and clinical response
Nyberg S; Nakashima Y; Nordstrom AL; Halldin C; Farde L
Published conference paper: JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY. 1996;206(1):133-144
Development of radioligands for the dopamine transporter
Muller L; Halldin C; Lundkvist C; Swahn CG; Foged C; Hall H; Karlsson P; Ginovart N; Nakashima Y; Suhara T; Farde L
Letter: LANCET. 1996;347(8996):264
Dopamine receptors in schizophrenia
Sedvall G; Farde L
Letter: LIFE SCIENCES. 1996;58(10):PL 187-92-192
[C-11]MDL 100907, a radioligand for selective imaging of 5-HT2A receptors with positron emission tomography
Lundkvist C; Halldin C; Ginovart N; Nyberg S; Swahn CG; Carr AA; Brunner F; Farde L
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):971-976
THE METABOLITE PATTERN OF [I-123] BETA-CIT DETERMINED WITH A GRADIENT HPLC METHOD
BERGSTROM KA; HALLDIN C; KUIKKA JT; SWAHN CG; TIIHONEN J; HILTUNEN J; LANSIMIES E; FARDE L
Published conference paper: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):959-964
SYNTHESIS OF NOR-BETA-CIT, BETA-CIT AND TRIMETHYLSTANNYL-BETA-CT
AMETAMEY SM; HALLDIN C; SWAHN CG; HALL H; SCHUBIGER PA; FARDE L
Published conference paper: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 1995;10:81-85
Positron emission tomography studies on D-2 dopamine receptor occupancy and plasma antipsychotic drug levels in man
Nyberg S; Nordstrom AL; Halldin C; Farde L
Other: SYNAPSE. 1995;19(4):297-300
LIPOPHILIC METABOLITE OF [I-123] BETA-CIT IN HUMAN PLASMA MAY OBSTRUCT QUANTITATION OF THE DOPAMINE TRANSPORTER
BERGSTROM KA; HALLDIN C; KUIKKA JT; SWAHN CG; TIIHONEN J; HILTUNEN J; LANSIMIES E; FARDE L
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1995;15(1-2):86
DECREASED D-1-DOPAMINE RECEPTOR-BINDING IN DRUG-NAIVE SCHIZOPHRENIC-PATIENTS EXAMINED BY PET
KARLSSON P; FARDE L; HALLDIN C; SEDVALL G
Published conference paper: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1995;15(1):19S-23S
POSITRON EMISSION TOMOGRAPHY STUDIES ON D-2 AND 5-HT2 RECEPTOR-BINDING IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS
FARDE L; NYBERG S; OXENSTIERNA G; NAKASHIMA Y; HALLDIN C; ERICSSON B
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 1995;152(2):173-178
D-2 DOPAMINE-RECEPTOR OCCUPANCY DURING LOW-DOSE TREATMENT WITH HALOPERIDOL DECANOATE
NYBERG S; FARDE L; HALLDIN C; DAHL ML; BERTILSSON L
Published conference paper: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1995;5:25-30
PET imaging of neuroreceptors in schizophrenia
Sedvall G; Pauli S; Karlsson P; Farde L; Nordstrom AL; Nyberg S; Halldin C
Published conference paper: CLINICAL NEUROPHARMACOLOGY. 1995;18:S121-S129
POSITRON EMISSION TOMOGRAPHY STUDIES ON DOPAMINE-RECEPTORS IN SCHIZOPHRENIA
FARDE L; NORDSTROM AL; KARLSSON P; HALLDIN C; SEDVALL G
Visa fler

Forskningsbidrag

MRI brain morphology and connectivity in schizophrenia; translational studies of four cohorts; importance of genetic and non-genetic risk factors for brain development and clinical outcome
Swedish Research Council
1 January 2018 - 31 December 2020
Longterm brain dysfunction after surgery and trauma
Swedish Research Council
1 January 2017 - 31 December 2020
PET-study of the time course for dopaminergic degeneration in Parkinson´s disease
Swedish Research Council
1 January 2017 - 31 December 2019
PET studies of the glutamate system in schizophrenia
Swedish Research Council
1 January 2016 - 31 December 2019
Respiratory control and cognitive function in anesthesia and surgery
Swedish Research Council
1 January 2014 - 31 December 2016
PET studies of brain biomarkers in schizophrenia
Swedish Research Council
1 January 2012 - 31 December 2015
Brain immune activation in schizophrenia - functional investigations of a novel antipsychotic drug target
Swedish Research Council
1 January 2012 - 31 December 2013
PET studies of neurotransmission systems in major psychiatric disorders
Swedish Research Council
1 January 2009 - 31 December 2011
PET ANALYSIS OF DOPAMINE D2 RECEPTORS IN SCHIZOPHRENIA
National Institute of Mental Health
1 May 1986 - 31 August 2000

Anställningar

Professor Emeritus/Emerita, Klinisk neurovetenskap, Karolinska Institutet, 2025-2027
Professor, Klinisk neurovetenskap, Karolinska Institutet, 2021-2024
Professor/Överläkare, Klinisk neurovetenskap, Karolinska Institutet, 1999-2021

Examina och utbildning

Docent, Allmän psykiatri, Karolinska Institutet, 1989

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI